JPS6140238A - 10_aryl_1,8_dihydroxyanthrone, manufacture and medicinal or cosmetic composition - Google Patents
10_aryl_1,8_dihydroxyanthrone, manufacture and medicinal or cosmetic compositionInfo
- Publication number
- JPS6140238A JPS6140238A JP12639185A JP12639185A JPS6140238A JP S6140238 A JPS6140238 A JP S6140238A JP 12639185 A JP12639185 A JP 12639185A JP 12639185 A JP12639185 A JP 12639185A JP S6140238 A JPS6140238 A JP S6140238A
- Authority
- JP
- Japan
- Prior art keywords
- group
- tables
- formulas
- hydrogen atom
- chemical formulas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims description 32
- 238000004519 manufacturing process Methods 0.000 title claims description 3
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 title description 2
- 239000002537 cosmetic Substances 0.000 title description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 45
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 33
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 239000000126 substance Substances 0.000 claims description 27
- 150000001875 compounds Chemical class 0.000 claims description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 22
- 125000000217 alkyl group Chemical group 0.000 claims description 21
- -1 CF_3 groups Chemical group 0.000 claims description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 18
- 125000003545 alkoxy group Chemical group 0.000 claims description 17
- 125000003118 aryl group Chemical group 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 15
- QBPFLULOKWLNNW-UHFFFAOYSA-N chrysazin Chemical compound O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O QBPFLULOKWLNNW-UHFFFAOYSA-N 0.000 claims description 14
- 150000005691 triesters Chemical class 0.000 claims description 13
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 claims description 9
- 229910021626 Tin(II) chloride Inorganic materials 0.000 claims description 9
- 239000001119 stannous chloride Substances 0.000 claims description 9
- 235000011150 stannous chloride Nutrition 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 229960001577 dantron Drugs 0.000 claims description 8
- 150000005690 diesters Chemical class 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 125000001424 substituent group Chemical group 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 5
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 4
- 238000001556 precipitation Methods 0.000 claims description 3
- AXHRXVXCOMMNLG-UHFFFAOYSA-N 1-hydroxy-10h-anthracen-9-one Chemical compound C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2O AXHRXVXCOMMNLG-UHFFFAOYSA-N 0.000 claims description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000002560 nitrile group Chemical group 0.000 claims 3
- DYSZXCJPBJXHNR-UHFFFAOYSA-N (8,9-diacetyloxy-10-thiophen-2-ylanthracen-1-yl) acetate Chemical compound C12=CC=CC(OC(C)=O)=C2C(OC(C)=O)=C2C(OC(=O)C)=CC=CC2=C1C1=CC=CS1 DYSZXCJPBJXHNR-UHFFFAOYSA-N 0.000 claims 1
- HWXLLNAYIZZBDS-UHFFFAOYSA-N 1,8-dihydroxy-10-(1,3-thiazol-2-yl)-10h-anthracen-9-one Chemical compound C12=CC=CC(O)=C2C(=O)C=2C(O)=CC=CC=2C1C1=NC=CS1 HWXLLNAYIZZBDS-UHFFFAOYSA-N 0.000 claims 1
- QYIPTEPRZGPMBI-UHFFFAOYSA-N 1,8-dihydroxy-10-(3-hydroxyphenyl)-10h-anthracen-9-one Chemical compound OC1=CC=CC(C2C3=CC=CC(O)=C3C(=O)C3=C(O)C=CC=C32)=C1 QYIPTEPRZGPMBI-UHFFFAOYSA-N 0.000 claims 1
- LHSYEMPUQITWPP-UHFFFAOYSA-N 1,8-dihydroxy-10-(3-methoxyphenyl)-10h-anthracen-9-one Chemical compound COC1=CC=CC(C2C3=CC=CC(O)=C3C(=O)C3=C(O)C=CC=C32)=C1 LHSYEMPUQITWPP-UHFFFAOYSA-N 0.000 claims 1
- YHTSSKFQQBCONG-UHFFFAOYSA-N 1,8-dihydroxy-10-(4-methoxyphenyl)-10h-anthracen-9-one Chemical compound C1=CC(OC)=CC=C1C1C2=CC=CC(O)=C2C(=O)C2=C(O)C=CC=C21 YHTSSKFQQBCONG-UHFFFAOYSA-N 0.000 claims 1
- JJMOZMZMMVEUMS-UHFFFAOYSA-N 1,8-dihydroxy-10-[3-(trifluoromethyl)phenyl]-10h-anthracen-9-one Chemical compound C12=CC=CC(O)=C2C(=O)C=2C(O)=CC=CC=2C1C1=CC=CC(C(F)(F)F)=C1 JJMOZMZMMVEUMS-UHFFFAOYSA-N 0.000 claims 1
- LSXPZLOKQYXPNN-UHFFFAOYSA-N 1,8-dihydroxy-10-thiophen-2-yl-10h-anthracen-9-one Chemical compound C12=CC=CC(O)=C2C(=O)C=2C(O)=CC=CC=2C1C1=CC=CS1 LSXPZLOKQYXPNN-UHFFFAOYSA-N 0.000 claims 1
- MSHCWYKYUBDLKM-UHFFFAOYSA-N 10-(2,4-dimethoxyphenyl)-1,8-dihydroxy-10h-anthracen-9-one Chemical compound COC1=CC(OC)=CC=C1C1C2=CC=CC(O)=C2C(=O)C2=C(O)C=CC=C21 MSHCWYKYUBDLKM-UHFFFAOYSA-N 0.000 claims 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- KHZIHFPFSXFUCV-UHFFFAOYSA-N [10-(3-methoxyphenyl)-8,9-di(propanoyloxy)anthracen-1-yl] propanoate Chemical compound C12=CC=CC(OC(=O)CC)=C2C(OC(=O)CC)=C2C(OC(=O)CC)=CC=CC2=C1C1=CC=CC(OC)=C1 KHZIHFPFSXFUCV-UHFFFAOYSA-N 0.000 claims 1
- WYFNKQYPMFPFEN-UHFFFAOYSA-N [8,9-di(propanoyloxy)-10-thiophen-2-ylanthracen-1-yl] propanoate Chemical compound C12=CC=CC(OC(=O)CC)=C2C(OC(=O)CC)=C2C(OC(=O)CC)=CC=CC2=C1C1=CC=CS1 WYFNKQYPMFPFEN-UHFFFAOYSA-N 0.000 claims 1
- 239000000047 product Substances 0.000 description 38
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 24
- 239000011541 reaction mixture Substances 0.000 description 22
- 238000002844 melting Methods 0.000 description 20
- 230000008018 melting Effects 0.000 description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 229960000583 acetic acid Drugs 0.000 description 18
- 239000013078 crystal Substances 0.000 description 16
- 238000000921 elemental analysis Methods 0.000 description 16
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 15
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000012362 glacial acetic acid Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 238000001819 mass spectrum Methods 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 235000019341 magnesium sulphate Nutrition 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- 239000012429 reaction media Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- 229910052786 argon Inorganic materials 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- RBBOWEDMXHTEPA-UHFFFAOYSA-N hexane;toluene Chemical compound CCCCCC.CC1=CC=CC=C1 RBBOWEDMXHTEPA-UHFFFAOYSA-N 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 229940099259 vaseline Drugs 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 3
- 150000004056 anthraquinones Chemical class 0.000 description 3
- 150000008425 anthrones Chemical class 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 229960001156 mitoxantrone Drugs 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- PLDWAJLZAAHOGG-UHFFFAOYSA-N 1-bromo-3-methoxybenzene Chemical compound COC1=CC=CC(Br)=C1 PLDWAJLZAAHOGG-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 2
- 241000009355 Antron Species 0.000 description 2
- ZCTQGTTXIYCGGC-UHFFFAOYSA-N Benzyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OCC1=CC=CC=C1 ZCTQGTTXIYCGGC-UHFFFAOYSA-N 0.000 description 2
- 208000001840 Dandruff Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 150000001491 aromatic compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000002681 magnesium compounds Chemical class 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 229940105132 myristate Drugs 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- HTDQSWDEWGSAMN-UHFFFAOYSA-N 1-bromo-2-methoxybenzene Chemical compound COC1=CC=CC=C1Br HTDQSWDEWGSAMN-UHFFFAOYSA-N 0.000 description 1
- HDRZKABGOGYHPC-UHFFFAOYSA-N 10,10-dihydroxyanthracen-9-one Chemical compound OC1(O)C2=CC=CC=C2C(=O)C2=CC=CC=C12 HDRZKABGOGYHPC-UHFFFAOYSA-N 0.000 description 1
- RXNZFHIEDZEUQM-UHFFFAOYSA-N 2-bromo-1,3-thiazole Chemical compound BrC1=NC=CS1 RXNZFHIEDZEUQM-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001062472 Stokellia anisodon Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 230000003656 anti-hair-loss Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003581 cosmetic carrier Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 229960002311 dithranol Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000002900 organolithium compounds Chemical class 0.000 description 1
- 150000002901 organomagnesium compounds Chemical class 0.000 description 1
- BSCHIACBONPEOB-UHFFFAOYSA-N oxolane;hydrate Chemical compound O.C1CCOC1 BSCHIACBONPEOB-UHFFFAOYSA-N 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- JZWFDVDETGFGFC-UHFFFAOYSA-N salacetamide Chemical group CC(=O)NC(=O)C1=CC=CC=C1O JZWFDVDETGFGFC-UHFFFAOYSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Inorganic materials O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
- C07C49/723—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups polycyclic
- C07C49/727—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups polycyclic a keto group being part of a condensed ring system
- C07C49/737—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups polycyclic a keto group being part of a condensed ring system having three rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
(57)【要約】本公報は電子出願前の出願データであるた
め要約のデータは記録されません。(57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.
Description
【発明の詳細な説明】
本発明は1.8−ジヒドロキシ−9−1ントロン又はア
ントラリンの新規な誘導体、とくに10の位置が芳香族
基によル鉦換さルている誘導体。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to novel derivatives of 1,8-dihydroxy-9-1 ntrone or anthralin, particularly those derivatives in which the 10-position is replaced by an aromatic group.
これら新規な誘導体のモノ−、ジー及びトリエステル、
これらの化合物の製造方法及びそれらの医学又は獣医学
における及び美容術における応用に関する・これら新規
銹導体はとくに抗増殖剤として癌性腫瘍、乾静及びいほ
の処置に、また消炎剤としてリウiチ、皮膚病、湿疹、
脂漏性及び薄膜性皮膚炎及び日焼の処置に応用される。mono-, di- and triester of these new derivatives,
Concerning processes for the preparation of these compounds and their applications in medicine or veterinary medicine and in cosmetology. These new rust conductors are useful, inter alia, as antiproliferative agents in the treatment of cancerous tumors, xerosis and tumors, and as anti-inflammatory agents. Chi, skin disease, eczema,
It is applied in the treatment of seborrheic and membranous dermatitis and sunburn.
美容術においてはこれらの化合物は抗座癒剤、ふけ防止
剤。In cosmetology, these compounds are anti-singing agents and anti-dandruff agents.
抗脂漏剤または脱毛防止剤として使用される・本発明の
10−アリール−1,8−ジヒドロキシ−アントロンは
下記の一般式(I):〔式中Ar は下記の式(I)〜
(iv) :すなわち2(式中R,,R2,R3,R4
及びR5は同一であるか又は異なるものであってかつ水
素原子、 ハロゲン原子、 −〇F5 基、 ヒ
トcIdFシル基・ 低級アルキル基、 低eシクロ
アルキル基、 低級ヒドロキシアルキル基、 低級ア
ルコキシ基、 ニトリル基。The 10-aryl-1,8-dihydroxy-anthrone of the present invention, which is used as an antiseborrheic agent or antihair loss agent, has the following general formula (I): [wherein Ar is the following formula (I) ~
(iv): That is, 2 (in the formula R,, R2, R3, R4
and R5 are the same or different and are hydrogen atom, halogen atom, -〇F5 group, human cIdF sil group/lower alkyl group, low e cycloalkyl group, lower hydroxyalkyl group, lower alkoxy group, nitrile Base.
の基t−表わしo r’及びrlは同一であるか又は異
なるものであってかつ水素原子又は低級アルキル基を表
わし、nは0又は1.2又は3の整数であシ。The group t-represents or r' and rl are the same or different and represent a hydrogen atom or a lower alkyl group, and n is an integer of 0 or 1.2 or 3.
R′及びR′ は水素原子、直鎖又は分岐鎖低級アルキ
ル基又はアリール基であってかつ場合によシ置換基を有
するものを表わす;但しR1乃至R50基のうち少なく
とも一個は水素原子でないものとする)
(I)
t
(lli )
R6
(R6はR1乃至R5の基について示し九定義のうちの
一つを有する)及び
(Iv)
のうちの一つで示される芳香族残基を表わす〕によって
表わすこオができる。本発明はまた一般式CI)の化合
物のモノ−、ジー及びトリエステルも包含する。R' and R' represent a hydrogen atom, a linear or branched lower alkyl group, or an aryl group, optionally having a substituent; provided that at least one of the R1 to R50 groups is not a hydrogen atom (I) t (lli ) R6 (R6 has one of the nine definitions shown for the groups R1 to R5) and (Iv) represents an aromatic residue shown by one of the following] This can be expressed as ko. The invention also includes mono-, di- and triesters of compounds of general formula CI).
R1乃至R5の基が/Sロゲン原子を表わすときはこの
基轄弗素又社塩素原子であることが好ましい。When the groups R1 to R5 represent a /S chlorine atom, this group is preferably a fluorine atom or a chlorine atom.
本明細書において低級アルキル基という用語は炭素数1
乃至6個のアルキル基好ましくはメチル。In this specification, the term lower alkyl group has 1 carbon atoms.
to 6 alkyl groups, preferably methyl.
エチル、lロピル、イングロビル、fチル、イソグチル
2 t−ブチル、にンテル、インにンチル又はヘキシル
基を意味する。Means an ethyl, lopyl, inglovir, f-thyl, isobutyl, tert-butyl, niter, ynethyl or hexyl group.
低級アルコキシ基という用語は炭素数1乃至4個のアル
コキシ基、とくにメトキシ、エトキシ。The term lower alkoxy refers to alkoxy groups having 1 to 4 carbon atoms, especially methoxy and ethoxy.
!ロボキシ又はイソ!ロボキシ基を意味する。! Roboxi or iso! means a roboxy group.
低級シクロアルキル基という用語はシクロプロピル、シ
クロブチル、シクロペンチル又はシクロヘキシル基を意
味する。The term lower cycloalkyl group means a cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl group.
低級ヒドロキシアルキル基という用語は炭素数1乃至3
個のヒドロキシアルキル基、とくにヒドロキシメチル、
2−ヒドロキシ・エチル又t′i2.3−ジヒドロキシ
グロビル基を意味する。The term lower hydroxyalkyl group has 1 to 3 carbon atoms.
hydroxyalkyl groups, especially hydroxymethyl,
2-Hydroxy ethyl or t'i2,3-dihydroxyglobyl group.
一般式CI)の化合物においてAr 基が式の芳香族残
基を表わすときは好ましい化合物は1) R,(又は
R5)が低級アルコキシ基又は式−N−COR’ C式
中R′は炭素数1乃至51!の直鎖又R#
は分岐鎖アルキル基を表わしBl は水素原子を表わ
す)の基を表わし、Rは水素原子又は低級アルコキシ基
を表わし、 R2、R4及びR5(又はR1)は水素原
子を表わすもの;
2) R2(又はR4)が−CF、 基、低級アル
コ中り基又はヒドロキシ基を表わし及びR4,R3,R
4(又はR2)及びR5は水素原子を表わすもの:及び
3)R3が低級アルコキシ基を表わし、 R,、R2゜
R4及びR5は水素原子を表わすもの;である。In the compound of the general formula CI), when the Ar group represents an aromatic residue of the formula, preferred compounds are 1) R, (or R5) is a lower alkoxy group or the formula -N-COR' C, where R' is the number of carbon atoms 1 to 51! straight chain or R# represents a branched alkyl group, Bl represents a hydrogen atom), R represents a hydrogen atom or a lower alkoxy group, and R2, R4 and R5 (or R1) represent a hydrogen atom. 2) R2 (or R4) represents -CF, group, lower alkoxy group, or hydroxy group, and R4, R3, R
4 (or R2) and R5 represent a hydrogen atom; and 3) R3 represents a lower alkoxy group; R,, R2° R4 and R5 represent a hydrogen atom;
好ましい実施態様によるとR6基は水素原子を表わす。According to a preferred embodiment, the R6 group represents a hydrogen atom.
一般式(I)の化合物としてとくに下記のものをあげる
ことができる:
1.8−ジヒドロキシ−10−(2’(N −2#豐2
′ジメチルグロノ9ノイル)アンノーフェニル〕アント
ロン。As compounds of the general formula (I), mention may be made in particular of the following: 1,8-dihydroxy-10-(2'(N -2#豐2
'dimethylgulono9noyl)annorphenyl]anthrone.
1.8−ジヒドロキシ−IQ−(2’、4’−ジメトキ
シフェニル)アントロン。1.8-Dihydroxy-IQ-(2',4'-dimethoxyphenyl)anthrone.
1.8−ジヒドロキシ−10−(4’−メトキシフェニ
ル)−アントロン。1.8-dihydroxy-10-(4'-methoxyphenyl)-anthrone.
1.8−ジヒドロキシ−10−(3’−)リフルオルメ
チルフェニル)−アントロン、
1.8”ジヒドロキシ−10−(3’−メトキシフェニ
ル)−アントロン。1.8-dihydroxy-10-(3'-)lifluoromethylphenyl)-anthrone, 1.8''dihydroxy-10-(3'-methoxyphenyl)-anthrone.
1.8−ジヒドロキシ−I Q −(3’−ヒドロキシ
フェニル)−アントロン。1.8-Dihydroxy-IQ-(3'-hydroxyphenyl)-anthrone.
1.8−ジヒドロキシ−10−(2’−メト命シーフェ
ニル)−アントロン。1.8-dihydroxy-10-(2'-methophenyl)-anthrone.
1.6−シヒドロキシー10− (2−’チェニル)−
アントロン。1,6-cyhydroxy-10- (2-'chenyl)-
Antron.
1.8−ジヒドロキシ−10−(2−チアゾリル)−ア
ントロン
一般式CI)の化合物のモノ−、ジー及びトリエステル
は下記一般式(■):
(式中、 Ar は一般式CI)の化合物について定義
したものと同一の意義を有するものであり・pは0又F
i婁であり、p−0のときRa Fi水素原子又は−〇
〇R,。基f:表わし、R9は−COR、。基を表わし
そしてP’嬬1でTo り * p =’のときl)
R,U水素原子を表わし、R8は水素原子又は−〇〇
R,。1.8-dihydroxy-10-(2-thiazolyl)-anthrone mono-, di- and triester of the compound of the general formula CI) are the following general formula (■): (wherein, Ar is the general formula CI) It has the same meaning as defined. p is 0 or F
i 婁 and when p-0, Ra Fi hydrogen atom or -〇〇R,. Group f: represents, R9 is -COR. represents a group, and P′ is 1. * When p = ', then l)
R, U represent a hydrogen atom, R8 is a hydrogen atom or -〇〇R,.
基を表わし、R2は−COR,。基を表わしそしてp′
は0であるか、あるいは、 it) R,は−COR
1゜基を表わし、R8及びR9は−COR,。基を表わ
しpは0である:R1゜は炭素数1乃至10個の直鎖又
は分岐鎖アルキル基、 シクロアル中ル基% 2−ピリ
ジル基、 2−チェニル基又はフェニル基であってかつ
場合により低級アルキル基、 低級アルコキシ基、
ハロゲンJ1. ニトロ基。represents a group, and R2 is -COR. represents a group and p′
is 0 or it) R, is -COR
1° group, and R8 and R9 are -COR. represents a group, p is 0: R1° is a straight or branched alkyl group having 1 to 10 carbon atoms, a cycloalyl group, a 2-pyridyl group, a 2-chenyl group, or a phenyl group, and optionally lower alkyl group, lower alkoxy group,
Halogen J1. Nitro group.
−CF、 基又はヒドロキシル官能基によジ置換され
ているものを表わす)によって表わさ詐得る化合物であ
るか、又は、該エステルの混合物である・炭素数1乃至
10個の直鎖又は分岐鎖アルキル基としてはとくにメチ
ル、 エチル、 グロビル。a straight-chain or branched alkyl compound having 1 to 10 carbon atoms; Examples include methyl, ethyl, and globil.
イソプロピル、 ブチル、 イソブチル、 1−ブ
チル、 パンチル、 イソはンチル、 ヘグテル、
ノニル及びデシル基をあげることができる・Rio基が
シクロアルキル基を表わすときはこの基はシクロノロビ
ル、 シクロッチル、 シクロはンチルX[シクロヘキ
シル基である・フェニル基がアル中ル基によ多置換され
ているときは置換基はメチル基、エチル基又はt−エチ
ル基であることが好ましい−
フェニル基がアルコキシ基により置′換されているとき
は置換基はメトヤシ又はエトキシ基であることが好まし
い。Isopropyl, butyl, isobutyl, 1-butyl, panthyl, isobutyl, hegter,
Examples include nonyl and decyl groups. When the Rio group represents a cycloalkyl group, this group is cyclonorobyl, cyclotyl, and cyclo is a cyclohexyl group. A phenyl group is polysubstituted with an alkyl group. When the phenyl group is substituted with an alkoxy group, the substituent is preferably a methoxy or ethoxy group.
フェニル基がハaグン原子によ多置換されているときは
置換基は塩素又は弗素原子であることが好ましい。When the phenyl group is polysubstituted with hagone atoms, the substituent is preferably a chlorine or fluorine atom.
上記の一般式(II)から明らかなとおシ本発明にヨル
エステルは10−アシル−暴、6−シヒドロキシーアン
トロンのモノ−又はジ−エステル又はそれらの異性体す
なわちIO−アクルー1.8−ジヒドロキシ−9−アン
トラノールの七ノー又はジ−エステルの形をしているか
また1jlQ−アシル−1,$−ジヒドロキシ−9−ア
ントラノールのトリエステルの形をしていることができ
る。As is clear from the above general formula (II), the yoluester according to the present invention is a mono- or di-ester of 10-acyl-cyclo,6-hydroxyanthrone or an isomer thereof, i.e., IO-acyl-1,8-dihydroxy It can be in the form of a heptano- or di-ester of -9-anthranol or as a triester of 1jlQ-acyl-1,$-dihydroxy-9-anthanol.
式(II)のエステルとしてとくに下記のものをあげる
ことができる:
1O−(3−メトキシフェニル)−1,8,9−トリア
セトキシ アントラセン
1O−(3−メトキシフェニル)−1,19−) j7
7’ Oi4ノイルオキシ アントラセン1O−(2−
チェニル)−i、g、9−トリアセトキシ アントラセ
ン
1O−(2−チェニル)−1,19−トリノロノ譬ノイ
ルオキシ アントラセン
1O−(2−チェニル)−1,8−ジピノ臂ロイルオキ
シ アントロン
本発明による一般式(I)の化合物は下記の反応式に従
って1.8−ジヒドロキシ アントラキノンから二工程
で製造される:
第1の工程は1.8−ジヒドロキシアントラキノン〔1
〕に芳香族カルボアニオンを反応させ、酸性とした後1
式(2)の化合物を得ることからなる。The following may be mentioned in particular as esters of formula (II): 1O-(3-methoxyphenyl)-1,8,9-triacetoxy anthracene 1O-(3-methoxyphenyl)-1,19-) j7
7' Oi4noyloxy anthracene1O-(2-
chenyl)-i,g,9-triacetoxy anthracene 1O-(2-chenyl)-1,19-trinoronomyloyloxy anthracene 1O-(2-chenyl)-1,8-dipinoyloxy anthrone General formula according to the invention ( The compound I) is prepared in two steps from 1,8-dihydroxy anthraquinone according to the following reaction scheme: The first step consists of 1,8-dihydroxy anthraquinone [1
] with an aromatic carbanion to make it acidic 1
It consists of obtaining a compound of formula (2).
第2の工程は中間化合物(2)を金属錫又は塩化第一錫
の存在下において還元しこれによって本発明の一般式(
I)の化合物を得ることからなる。The second step is to reduce the intermediate compound (2) in the presence of metallic tin or stannous chloride, thereby obtaining the general formula (
It consists of obtaining the compound of I).
芳香族カルボアニオンは有′機リチウム化合物から調製
するかまたは有機マグネシウム化合物から調製すること
ができ石。Aromatic carbanions can be prepared from organolithium compounds or from organomagnesium compounds.
芳香族有機リチウム化合物は二つの異なる方法によって
調製することができる:
第1の方法はブチルリチウム又はそのテトラメチルエチ
レンジアミンとの錯体を、f換基(単数又は複数〕によ
υ金属と結合させようとしている炭素が活性化されてい
る芳香族化合物と反応させることからなる・
とくにD−W、5locutnほか、 J、O,C’、
皿箆第3563頁又はV、5niackuaほか、 J
、O,C,44(+97’/)第4803頁などに記載
の方法が利用できる◎芳香族リチウム化合物の第2の調
製方法はP。Aromatic organolithium compounds can be prepared by two different methods: The first method would combine butyllithium or its complex with tetramethylethylenediamine with the υ metal via the f substituent(s). It consists of reacting with an aromatic compound in which the carbon is activated, especially D-W, 5locutn, etc., J, O, C',
Sarasho No. 3563 or V, 5 Niackua et al., J
, O, C, 44 (+97'/), page 4803, etc. can be used. ◎The second method for preparing aromatic lithium compounds is P.
Beakほか、 Ace、 Chern、 R@g、
1982第306頁及びW、E、Parhamほか、
Arc、 Chem、 Rag、 1982第300頁
記載の方法に従ってノ・ロゲン化芳香族誘導体とくに臭
化誘導体t−ブチルリチウムにより処理することからな
る。Beak et al., Ace, Chern, R@g,
1982, p. 306 and W. E. Parham et al.
It consists of treatment with a non-rogenated aromatic derivative, in particular the brominated derivative t-butyllithium, according to the method described in Arc, Chem, Rag, 1982, page 300.
マグネシウム化合物から芳香族カルボアニオンを形成さ
せるときは、前記の方法におけるとおフ。When forming an aromatic carbanion from a magnesium compound, follow the steps in the above method.
ハロゲン化芳香族誘導体を用い、これを従来の方法に従
って無水溶媒テトラヒドロフラン又はエーテルなどの中
でマダネシウム化合物に転化する。A halogenated aromatic derivative is used which is converted to a madanesium compound in an anhydrous solvent such as tetrahydrofuran or ether according to conventional methods.
芳香族リチウム化合物t−1,8−ジヒドロキシアント
ラキノンに反応させる方法は2芳香族iグネクウム化合
物の場合とは異なって、この方法がアントラキノン核の
10の位置にあるカルボニルへの選択的付加を行うので
とくに好ましい方法である。芳香族マグネシウム化合物
の場谷にはこの現象が生起せず若干の場合には9の位置
への付加が観察される。The method for reacting the aromatic lithium compound t-1,8-dihydroxyanthraquinone is different from that for the 2-aromatic i-gnecum compound because this method selectively adds to the carbonyl at the 10 position of the anthraquinone nucleus. This is a particularly preferred method. This phenomenon does not occur in the case of aromatic magnesium compounds, and in some cases addition to position 9 is observed.
更に、1.8−ジヒドロキシアントラキノンに対して少
なくとも4モル当量の大きく過剰の芳香族リチウム化合
物を用いると、公知の方法におけるように、アントロン
核の10の位置が置換された芳香族誘導体を得るのに1
又は8の位置のヒドロキシル官能基の保Ilt行う必要
のないことが認められたー
C1g−ジヒドロキシアントラキノンの芳香族リチウム
化合物の付加反応は一般にエチルニーチル又はテトラヒ
ドロフランのごとき無水溶媒媒体中、−80乃至0°C
の温度においてエーテル又はテトラヒドロフラン中の芳
香族リチウム化合物の溶液を、これと同じ溶媒中の1.
6−ジヒドロキシアントラキノンの溶液に加ることによ
って行われる。Furthermore, the use of a large excess of aromatic lithium compounds of at least 4 molar equivalents relative to 1,8-dihydroxyanthraquinone makes it possible to obtain aromatic derivatives substituted in position 10 of the anthrone nucleus, as in the known process. to 1
It has been found that it is not necessary to carry out the retention of the hydroxyl function in the 8-position or -C1g-dihydroxyanthraquinone with an aromatic lithium compound generally in an anhydrous solvent medium such as ethylnityl or tetrahydrofuran at -80° to 0°. C
A solution of an aromatic lithium compound in ether or tetrahydrofuran at a temperature of 1.
It is carried out by adding to a solution of 6-dihydroxyanthraquinone.
添加後反応混合物大上記と同一の温度に訃いて30分乃
至2時間の間攪拌する。反応の終了は薄層クロマトグラ
フィーにより1.8−ジヒドロキシアントラキノンが存
在しなくなったことによって確認する。After the addition, the reaction mixture is kept at the same temperature as above and stirred for 30 minutes to 2 hours. Completion of the reaction is confirmed by thin layer chromatography by the absence of 1,8-dihydroxyanthraquinone.
ついで室温に訃いて反応混合物を酸性化し1次に有機相
を水洗し、無水硫酸!グネシウム上で乾燥させる。The reaction mixture was then allowed to cool to room temperature, acidified, and the organic phase was washed with water and treated with sulfuric anhydride. Dry on magnesium.
溶媒の蒸発後、中間化合物(2)すなわち10−717
−ルー 1.8 、 I O−トリヒドロキシアントロ
ンを再結晶又はシリカゲル−クロマトグラフィーによシ
精製する。After evaporation of the solvent, intermediate compound (2) i.e. 10-717
1.8, I O-trihydroxyanthrone is purified by recrystallization or silica gel chromatography.
反応が芳香族!グネシウム化合物を用いて行なわれると
きは1反応条件は芳香族リチウム化合物を使用する場合
に適用されるものと同じであるが・ただし添加終了後に
室温に戻し、数時間攪拌を続け、場合によっては溶媒o
’R5tt−併用し、そして薄層クロマトグラフィーに
よる1、8−ジヒドロキシアントラキノンの消失が確認
されるまで行なうO
本発明による一般式CI)の化合物を得るための方法の
第2工程は、10−アリール−1,8,IO−トリヒド
ロキシアントロン(2)を還元することからなり、この
還元反応は酢酸媒体中、塩化第−鉄又は金属錫と濃塩酸
との存在下において行なわれる。The reaction is aromatic! When carried out using a magnesium compound, 1 the reaction conditions are the same as those applied when using an aromatic lithium compound, except that after the addition is complete, the temperature is returned to room temperature, stirring is continued for several hours, and if necessary the solvent is o
'R5tt- and carried out until the disappearance of the 1,8-dihydroxyanthraquinone is confirmed by thin layer chromatography. The second step of the process for obtaining the compounds of general formula CI) according to the invention comprises It consists of reducing -1,8,IO-trihydroxyanthrone (2), the reduction reaction being carried out in an acetic acid medium in the presence of ferrous or metallic tin chloride and concentrated hydrochloric acid.
この反応は通常、室温において1/2乃至5時間行なわ
れ1反応の終了は薄層クロマトグラフィーによる出発原
料の不存在によシ決定する・反応が完了していないとき
は反応混合物を水浴上で処理することができる。The reaction is usually carried out at room temperature for 1/2 to 5 hours, and completion of the reaction is determined by the absence of starting materials by thin layer chromatography.If the reaction is not complete, the reaction mixture is placed on a water bath. can be processed.
室温に戻った後に反応混合物を水に注ぎ、これによって
目的生成物の沈澱を生じさせ、ついでこれを適当な溶媒
から再結晶させる。After returning to room temperature, the reaction mixture is poured into water, which causes precipitation of the desired product, which is then recrystallized from a suitable solvent.
一般式(II)のエステルは、一般式CI)の10−ア
リール−■・ g−ジヒドロキシアントラント適当な酸
無水物とを、数滴のピリジンの存在下でかつ場合によっ
ては反応混合物を50乃至+ 33’Cの温度に加熱し
て反応させるか又は上記アントロン誘導体をピリジンの
存在下においてトルエンのごとき芳香族#!岸中の化学
当量の酸クロライドと反応させることによって得られる
。Esters of the general formula (II) can be prepared by reacting the 10-aryl-g-dihydroxyanthantes of the general formula CI) with a suitable acid anhydride in the presence of a few drops of pyridine and optionally reducing the reaction mixture from The above anthrone derivatives can be reacted by heating to a temperature of +33'C or the above anthrone derivatives can be reacted with an aromatic compound such as toluene in the presence of pyridine. It is obtained by reacting with a chemical equivalent of acid chloride in the liquid.
モノ−、ジー又はトリエステルの生成は反応させる酸無
水物又は酸クロライドのモル比及び反応時間によル変動
する@
本発明は更に一般式(I)又は(ff)の化合物の少な
くとも1種を有効成分として含んでいる医薬及び化粧料
組成物も目的とする。The production of mono-, di-, or triester varies depending on the molar ratio of the acid anhydride or acid chloride to be reacted and the reaction time. Also of interest are pharmaceutical and cosmetic compositions containing it as an active ingredient.
これらの組成物において有効成分の濃度は投与の経路に
応じて通常o、oos乃至70重量係の範囲で変動する
ー
これらの組成物はそのほかに不活性な又は薬方学的に活
性な添加物たとえば結合剤、充填剤、稀釈剤、増粘剤、
防腐剤などを含む仁とができる@経口投与する組成物は
また風味剤も含有し得るー局所投与する組成物はポマー
ド、軟膏、クリーム、ゲル、チンキ、 溶W、ローシ目
ン、スグレー・懸濁液・微粉又はシャングーの形とする
ことができる。In these compositions, the concentration of active ingredient varies depending on the route of administration, usually ranging from 0,000 to 70,000 by weight; these compositions may also contain other inert or pharmacologically active excipients. For example, binders, fillers, diluents, thickeners,
Compositions for oral administration may also contain flavoring agents, including preservatives, etc. Compositions for topical administration may include pomades, ointments, creams, gels, tinctures, molten W, Roshime, sougere suspension, etc. It can be in the form of a suspension, a fine powder, or a shanggu.
この実施形式によると1組成物+00,9あたシ有効成
分を0.01乃至5g含有する組成物1乃至5gを、−
1回又は2回で一皮膚の処置すべき域に適用する。According to this embodiment, 1 composition + 0.9 g of a composition containing 0.01 to 5 g of an active ingredient, -
Apply once or twice to the area of skin to be treated.
経口又は非経口投与する組成物は顆粒・ゼラチンカグセ
ル、カグセル・シロッf、飲用s濁液。Compositions for oral or parenteral administration include granules/gelatin capsules, capsules/silo f, and drinkable suspensions.
装入夛飲用粉末、或いはまた注入可能の溶液又は懸濁液
の形とすることができる。The dosage may be in the form of a drinkable powder or alternatively an injectable solution or suspension.
経口又は非経口用組成物は、一般に、成人で一日あた9
1回に又は数回に分けて、O,OS乃至5Iの有効成分
を投与する。Oral or parenteral compositions are generally administered at 90% per day for adults.
The active ingredients O, OS to 5I are administered once or in several doses.
試験結果は本発明による組成物が種々の医薬用4
又は化粧料用担体と混合したとき、良好な活性を有す
ることを示した。The test results show that the composition according to the present invention has various medicinal properties.
It was also shown to have good activity when mixed with a cosmetic carrier.
本発明による化合物音製造する実施例を以下に示すe
実施例1
a)無水テトラヒドロフラン(T)iF) IQ□ c
ts 中のN−ピバノイルアニリン7811に不活性
雰囲気中、O’Cにおいてn−グチル−リチウム+00
副3(2・5M)を添加した。Examples of preparing compounds according to the present invention are shown below. Example 1 a) Anhydrous tetrahydrofuran (T) iF) IQ□c
n-glythyl-lithium+00 at O'C in an inert atmosphere to N-pivanoylaniline 7811 in ts
Added Vice 3 (2.5M).
添加後反応混合物を室温に24時間放置した。After the addition, the reaction mixture was left at room temperature for 24 hours.
次にO1′Cにおいて無水テトラヒドクフラン(THF
)IQQz 中の1.8−ジヒドロキシアントラキ
ノン5Iの溶液を一滴ずつ加えたー室温において4時間
攪拌した後、その溶液を酢酸75crR’で酸性にした
。水500副 に注ぎジクロルメタンにょシ抽出した。Next, at O1'C, anhydrous tetrahydrocufuran (THF
) A solution of 1,8-dihydroxyanthraquinone 5I in IQQz was added dropwise - after stirring for 4 hours at room temperature, the solution was acidified with 75 crR' of acetic acid. It was poured into 500 parts of water and extracted with dichloromethane.
有機相を硫酸!ダネシウム上で乾燥させ次に減圧下で濃
縮した。所期の生成物はシリカゲル−クロマトグラフィ
ーによ)精製した。かくして融点257−259°Cの
I O−(2’(N −2’、 2’リメチル!ロノ9
ノイル)アミノ−フェニル〕−1,11,lo−)リヒ
ドロキクアントロンの黄色結晶1.9が得られる。Sulfuric acid for the organic phase! Dry over danesium and concentrate under reduced pressure. The expected product was purified (by silica gel chromatography). Thus IO-(2'(N-2', 2'remethyl!lono9) with melting point 257-259°C
1.9 yellow crystals of noyl)amino-phenyl]-1,11,lo-)lihydroquiquantrone are obtained.
NMRのスはり)xt;を所期の生成物の構造に一致し
た。The NMR spectrum (xt) was consistent with the structure of the desired product.
元素分析:c25H23o5N
計算値: C71,92,H5,55,019,16,
N 3.35実測値: 71.71. 5.56.
+8.92. 3・43b)上記a)において得られ
た1O−(2’(N+ 2#、 21ジメチルグロノ母
ノイル)アミノーフェニ&)−1,8,IQ−17ヒド
ロキシアントロン250qを氷酢酸253 中に懸濁さ
せたものに不活性雰囲気中において塩化第一錫40(I
q及び濃塩酸数滴を加えたー
室温において2時間攪拌した後1反応混合物を水100
d へ注いだ。所期の生成物は沈澱し・これをf別し乾
燥させた0次にジクロルメタン5゜1:1llIsK溶
解し、シリカ2gの存在下において攪拌した・溶液t−
濾過した後、減圧下に濃縮した。所期の生成物はへキサ
ン添加によって沈澱させついでヘキサンを除去して乾燥
させた。かくして融点176−177°Cの黄色結晶1
00岬が得られた・NMRx−eクトルならびに質量ス
はクトルm/e401は目的の生成物に一致した。Elemental analysis: c25H23o5N Calculated value: C71,92,H5,55,019,16,
N 3.35 Actual value: 71.71. 5.56.
+8.92. 3.43b) 250 q of 1O-(2'(N+ 2#, 21 dimethylgulononatomyl)aminophenyl)-1,8,IQ-17 hydroxyanthrone obtained in a) above was suspended in 253 ml of glacial acetic acid. Stannous chloride 40(I) in an inert atmosphere
q and a few drops of concentrated hydrochloric acid - After stirring for 2 hours at room temperature, the reaction mixture was diluted with 100 ml of water.
Pour into d. The desired product was precipitated, separated and dried, then dissolved in dichloromethane 5° 1:1lIsK and stirred in the presence of 2 g of silica.
After filtering, it was concentrated under reduced pressure. The desired product was precipitated by the addition of hexane and was dried by removing the hexane. Thus yellow crystals 1 with a melting point of 176-177°C
00 cape was obtained. NMR x-e vector and mass mass m/e 401 were consistent with the desired product.
実施例2
メトキシ−フェニル)アントロンの調製a)無水xfs
、x、−fs、 50 cm’ 中(D I 、 3−
ジメトキシベンゼン22.1.9の溶液に室温でアルプ
ン気流中においてn−プテルーリテウA1003’(I
,6M)を添加した。24時間後にこの溶液を速かに一
78°Cの無水THF l 503 中C)1.8−
ジヒドロキシアントラキノン5.9の懸濁液に加えたー
反応終了後1反応媒体を木酢ff503’によシ酸性に
した。水(200C!13 )”t”洗浄し、硫酸マグ
ネシウム上で乾燥させ喪後に有機相を減圧下で濃縮し次
にシリカゲルクc1!トダラフイーによシ精製した。か
くして融点270’Cの1O−(2’、4’−ジメトキ
シフェニル)−L、S、lo−)リヒドロキシアントロ
ンの黄色結晶200++vが得られた―
NMRスペクトルH250MHzは所期の生成物の構造
と一致した。Example 2 Preparation of methoxy-phenyl)anthrone a) Anhydrous xfs
, x, -fs, 50 cm' (DI, 3-
n-Pterurite A1003' (I
, 6M) was added. After 24 hours, the solution was immediately dissolved in anhydrous THF at 78°C.
After completion of the reaction, the reaction medium was acidified with wood vinegar ff503'. After washing with water (200C!13) and drying over magnesium sulfate, the organic phase was concentrated under reduced pressure and then silica gel c1! It was purified by Todarahui. Thus, 200++v yellow crystals of 1O-(2',4'-dimethoxyphenyl)-L,S,lo-)lihydroxyanthrone with a melting point of 270'C were obtained - the NMR spectrum H250MHz was consistent with the structure of the expected product. Agreed.
元素分析:C2□H1806
計算値: C69,85,H4,79
実測値: 70.54. 4.B5
b)上記a)に訃いて得られfc+□−(2’、4’−
ジメトキシフエニル)−1,g、IQ−トリヒドロキシ
アントロン100岬を氷酢酸25jfl K溶解した
溶液に不活性雰囲気中において塩化第一錫200q及び
濃塩酸数滴を加えた・反応混合物を室温において5時間
攪拌し次に水100cm に注ぎ所期の生成物を沈澱
させr過し乾燥させた。Elemental analysis: C2□H1806 Calculated value: C69,85, H4,79 Actual value: 70.54. 4. B5 b) fc+□-(2', 4'-) obtained by replacing a) above
200 q of stannous chloride and a few drops of concentrated hydrochloric acid were added in an inert atmosphere to a solution of 1,0 g of IQ-trihydroxyanthrone dissolved in 25 k of glacial acetic acid. The mixture was stirred for an hour and then poured into 100 cm 2 of water to precipitate the desired product, filtered and dried.
かくして融点152°Cのクリーム色の粉末5(lvが
得られた。A cream-colored powder 5 (lv) with a melting point of 152°C was thus obtained.
質量スペクトルm/e : 362
実施例3
キシフェニル)アントロンの調製
1) m水テトラヒドロフラン5 Q cm ’中のp
−ブロムアニソール2811の溶液に、−78°Cでア
ルゴン気流中においてn−グチルリチウム100(:f
f5(I,6M)を添加した。1時間で溶液を常温に戻
したーこれを臭素アンダールに移し、無水THF 30
0 cm’中Of、s 8−’;e トo*V ・7ン
トラキノン7.29の溶液に温度−72°C,アルゴン
気流中において加えた。添加終了後反応混合物t−24
時間て室温に戻し危。次に氷酢酸5035で反応混合物
を酸性にし、水500の3へ注いだ。Mass spectrum m/e: 362 Example 3 Preparation of xyphenyl)anthrone 1) p in m water tetrahydrofuran 5 Q cm'
- To a solution of bromoanisole 2811 was added n-glylithium 100 (: f
f5(I, 6M) was added. The solution was brought to room temperature in 1 hour - transferred to bromine andard and diluted with anhydrous THF 30
Of, s 8-' in 0 cm'; After completion of addition reaction mixture t-24
Take some time to bring it back to room temperature. The reaction mixture was then acidified with 5035 ml of glacial acetic acid and poured into 500 ml of water.
ジクロルメタンにより抽出の後、有機相を硫酸マグネシ
ウム上で乾燥させ次に減圧下に濃縮した・かくして、シ
リカゲルクロマトグラフィーを行った後に、所期の生成
物3.49が得られた。トルエン−ヘキサン混合物から
再結晶させた後に、融点+72−173°Cの10.−
(4’−メトキシフェニル)1.8.IO−トリヒドロ
中シアントロンの黄色結晶が得られた〇
NMRスペクトルは所期の生成物の構造に一致した。After extraction with dichloromethane, the organic phase was dried over magnesium sulphate and concentrated under reduced pressure. Thus, after silica gel chromatography, the expected product 3.49 was obtained. 10. after recrystallization from a toluene-hexane mixture with a melting point of +72-173°C. −
(4'-methoxyphenyl) 1.8. Yellow crystals of cyanthrone in IO-trihydro were obtained. The NMR spectrum was consistent with the structure of the desired product.
元素分析:C2,馬、05
計算値: C72,40,)I 4.63.022.9
7実測値: 72.47・ 4.61. 22.87
b)上記a)において得られたI O−(4’−メトキ
シフェニル)−1,8,lo−)リヒドロキシアントロ
ン200岬を氷酢酸10crII5 に溶かした溶液に
塩化第一錫200岬と数滴の濃塩酸とを添加した。不活
性雰囲気中において2時間攪拌を続けた。水+00cI
R中において反応媒体から沈澱させて所期の生成物が得
られた。かくして緑黄色の粉末が得られた;このものは
215°Cから分解した。Elemental analysis: C2, Horse, 05 Calculated value: C72,40,)I 4.63.022.9
7 Actual measurement value: 72.47・4.61. 22.87
b) Add a few drops of 200 capes of stannous chloride to a solution of 200 caps of I O-(4'-methoxyphenyl)-1,8,lo-)lihydroxyanthrone obtained in a) above dissolved in 10 crII5 of glacial acetic acid. of concentrated hydrochloric acid was added. Stirring was continued for 2 hours in an inert atmosphere. Water +00cI
The expected product was obtained by precipitation from the reaction medium in R. A green-yellow powder was thus obtained; this decomposed from 215°C.
NMRスペクトル及び質量スペクトル(m/e=332
)は所期の生成物の構造と一致した。NMR spectrum and mass spectrum (m/e=332
) was consistent with the structure of the expected product.
元素分析:C2,H1604
計算値: C75,89,ii 4−85.019−2
5実測値: C75,7B、 H4,80,019,2
6実施例4
1.8−ジヒドaキシ−10−(3’−トリフルオロメ
チル フェニル)−アントロンの調製
a)無水THF I Q Q傭3中の3−トリフルオロ
メチルフロムベンゼン25gの溶液に、−78°C。Elemental analysis: C2, H1604 Calculated value: C75,89,ii 4-85.019-2
5 Actual measurements: C75,7B, H4,80,019,2
6 Example 4 Preparation of 1.8-dihydro-10-(3'-trifluoromethylphenyl)-antrone a) In a solution of 25 g of 3-trifluoromethylfrombenzene in anhydrous THF IQQ 3, -78°C.
アルゴン気流中において、n−ブチルリチウムI00c
M (I,6M)を加えた。In an argon stream, n-butyllithium I00c
M (I,6M) was added.
添加終了後1反応媒体を室温に戻した。After the addition was complete, the reaction medium was returned to room temperature.
得られた溶液を不活性雰囲気中において一滴ずつ一78
°Cの無水THF 2003 中の1.−8−ジヒド
ロキシアントラキノン7.2gの懸濁液に加えた。The resulting solution was placed drop by drop in an inert atmosphere.
1 in anhydrous THF 2003 °C. It was added to a suspension of 7.2 g of -8-dihydroxyanthraquinone.
反応混合物をこの温度に1時間保ち次に室温に戻した。The reaction mixture was kept at this temperature for 1 hour and then allowed to warm to room temperature.
次に反応溶液を氷酢酸5QC1l+’の添加によシ酸性
にした・反応媒体を水200cf1g3で洗浄し、乾燥
させ濃縮した後にシリカゲル塔で精製した。所期の生成
物1.211を単離しトルエンーヘキサン混合物から再
結晶させた。融点222−223°Cの1O−(3’−
トリフルオロメチルフェニル)−1,8,10−トリヒ
ドロキシアントロンの黄色結晶が得られた。The reaction solution was then acidified by the addition of 5QC1l+' of glacial acetic acid.The reaction medium was washed with 200cf1g3 of water, dried and concentrated before being purified on a silica gel column. The desired product 1.211 was isolated and recrystallized from a toluene-hexane mixture. 1O-(3'-
Yellow crystals of trifluoromethylphenyl-1,8,10-trihydroxyanthrone were obtained.
NMRスペクトルH250MHz は所期の生成物の構
造と一致した・
元素分析:C21H13F、04
計算値: C65,30,H3,39
実測値: 64.95. 3.35
b)上記a)において得られたI O−(3’−トリフ
ルオロメチルフェニル)−1,3,IO−トリヒドロキ
シアントロン150■を氷酢酸25ffl’に溶解した
溶液に窒素気流中において塩化第一錫200キと濃塩酸
数滴とを加えた。反応混合物を室温において3時間攪拌
した抜水1oocrn の添加により所期の生成物を沈
澱させた。生成物をf別し次に乾燥させた。融点210
−211°Cの黄色粉末50qが得られた。NMR spectrum H250MHz was consistent with the structure of the expected product. Elemental analysis: C21H13F, 04 Calculated value: C65,30, H3,39 Observed value: 64.95. 3.35 b) Add 150 μl of IO-(3'-trifluoromethylphenyl)-1,3,IO-trihydroxyanthrone obtained in a) above to 25 ffl' of glacial acetic acid in a nitrogen stream. 200 kg of stannous chloride and several drops of concentrated hydrochloric acid were added. The reaction mixture was stirred at room temperature for 3 hours and the desired product was precipitated by addition of 1 oocrn of water. The product was separated and then dried. Melting point 210
50q of yellow powder at -211°C was obtained.
質量スペクトル: m/e = 370実施例よ
無水THF4’0−中のマグネシウムλ、7?に窒素気
流中においてTHF’i還流させながらm−ブロムアニ
ソールλθ、ざ?を加えた。添加終了後1時間還流を続
けた6v<に反応混合物を、窒素気流中、0℃において
無水THFAOBd中の1.ざ−ジヒPロキシアントラ
キノンsyの懸濁液に一滴ずつ加えた。反応混合物をl
夜室温に放置した後r時間jQ℃に加熱する。Mass spectrum: m/e = 370 Example Magnesium λ, 7? in anhydrous THF 4'0- While refluxing THF'i in a nitrogen stream, m-bromoanisole λθ, za? added. After the addition was complete, the reaction mixture was refluxed for 1 hour and the reaction mixture was dissolved in anhydrous THFAOBd at 0° C. in a stream of nitrogen. It was added drop by drop to the suspension of zyanthraquinone sy. l reaction mixture
After being left at room temperature overnight, it was heated to jQ°C for r hours.
反応混合物を氷酢酸りdの添加により酸性にした後、水
15θCaを加えた。生成物をエチルエーテル(t o
ocd)で抽出し有機相を乾燥させ次後に真空中にお
いて濃縮した。次に反応生成物をシリカゲルクロマトグ
ラフィーにより精製して1O−(3′−メトキシフェニ
ル)−i、I、tO−トリヒドロキシアントロン/、2
?f得fc。The reaction mixture was made acidic by the addition of glacial acetic acid, and then 15θCa of water was added. The product was dissolved in ethyl ether (t o
ocd) and the organic phase was dried and then concentrated in vacuo. The reaction product was then purified by silica gel chromatography to obtain 1O-(3'-methoxyphenyl)-i,I,tO-trihydroxyanthrone/,2
? f get fc.
無水THFjOcd中のm−ブロムアニソール21?の
溶液[−71r℃、アルゴン気流中において、n−ブチ
ルリチウム1OOcrI(I,6M)を加えた。次に得
られた溶液を臭素アンゾールへ移し、−7r℃、アルゴ
ン気流中において無水THFJorta中のl、r−ジ
ヒrロキシ アントラキノン7.29の懸濁液に加えた
。添加終了後反応混合物を2μ時間で室温に戻した。次
に氷酢酸SOmKより酸性にした稜水soo、1(で洗
浄した。有機相を分離した後、硫酸マグネシウム上で乾
燥させ減圧下に濃縮した7所期の生成物をトルエンの添
加[よって結晶化した。かぐして融点λOコ℃のt O
−(J’−メトキシフェール)−t、I、tO−トリヒ
ドロキシ アントロンμ、2?が単離されたO
NMRスペクトルは所期生成物の構造と一致した0
元素分析:【】21H1605
計算値” 072,4oHa、65022.97実測値
: 72.75 4.61 22.62b)上記の方
法a)又はa’)&Cよって得られたt O−(j’−
メトキシフェニル゛)−tlg、t。m-bromoanisole 21 in anhydrous THFjOcd? A solution of n-butyllithium 1OOcrI (I, 6M) was added at -71rC in an argon stream. The resulting solution was then transferred to a brominated anzole and added to a suspension of 7.29 g of l,r-dihyroxy anthraquinone in anhydrous THF Jorta at -7rC under a stream of argon. After the addition was complete, the reaction mixture was allowed to return to room temperature for 2 μh. The desired product was then washed with water soo, acidified with glacial acetic acid SOmK. After separation of the organic phase, the desired product was dried over magnesium sulfate and concentrated under reduced pressure. The melting point λO is tO in °C.
-(J'-methoxypher)-t,I,tO-trihydroxy anthrone μ, 2? The isolated O NMR spectrum was consistent with the structure of the desired product 0 Elemental analysis: []21H1605 Calculated value 072,4oHa, 65022.97 Observed value: 72.75 4.61 22.62b) Above t O-(j'-) obtained by method a) or a')&C
methoxyphenyl)-tlg, t.
−トリヒドロキシ アントロン31を木酢酸約100t
dに溶解した溶液に不活性雰囲気中で塩化第一錫3v、
次に濃硫@ j crdを加えた。反応混合物を室温に
おいて2時間攪拌した後、水500a/Lの添加にニジ
所期の生成物を沈澱させた。乾燥後、融点ir’y℃の
黄色粉末2.79が得られた。- Trihydroxy anthrone 31 to about 100 tons of wood acetic acid
3v of stannous chloride in an inert atmosphere in a solution dissolved in d,
Next, concentrated sulfur @ j crd was added. After stirring the reaction mixture for 2 hours at room temperature, the desired product was precipitated on addition of 500 a/L of water. After drying, a yellow powder with a melting point of 2.79 °C was obtained.
NMRスペクトルは所期生成物の構造と一致した。The NMR spectrum was consistent with the structure of the expected product.
元素分析=021H1604
計算値” ”’75.89 H’4.85019.25
実測値: 75,71 4,92 19.24実施例
t
フェニル)−アントロンの調製
実施例jにおいて得られfcl・r−ジヒtロキシー/
0− (、?’−メトキシフェニル)−アントロン2
00〜を不活性雰囲気中において酢酸35−と臭@/7
cjとの溶液に加えた。これを700−110℃に加熱
しかつ薄層クロマトグラフィーによって反応の進行を追
及【7几。原料が完全に消失した後、溶液を水約200
64へ注ぎ、沈#t−F別した。乾燥後に生成物をジク
ロルメタン/!Ocdに溶解し、次にシリカ3?の存在
下において攪拌した。溶液を濾過した後に減圧下で濃縮
し友。所期の生成物をヘキサン添加によシ結晶化しに、
か(して融点コ04c℃の黄色結晶itowqが得られ
ta
NMRスペクトルは所期の生成物の構造に一致した6
元素分析=028H1404
計算値: 075.46 H4,45020,11実測
値: 75.57 μ、57 19.96実施例7
i、r−ジヒ?ロキシーt O(J’−メトキシ フェ
ニル)−アントロンの調製
a)無水THF/jd中のマグネシラムコ、jjVに窒
素気流中においてTHFを還流させながら0−ブロムア
ニソールt A、コVを加えた。還流は添加終了後も/
/J時間続けた。次に得らtまた溶液を窒素気流中θ℃
において無水THFjO−中のl、r−ジヒraキシ
アントラキノンjvの懸濁液に一滴ずつ加えた。反応混
合物を一夜室温に放置した後、氷酢酸9mKより酸性と
し水/60−を加えた。Elemental analysis = 021H1604 Calculated value "'75.89 H'4.85019.25
Actual value: 75,71 4,92 19.24 Example t Preparation of phenyl)-anthrone fcl·r-dihydroxyloxy/
0- (,?'-methoxyphenyl)-anthrone 2
00~ in an inert atmosphere with acetic acid 35- and odor @/7
Added to the solution with cj. This was heated to 700-110°C and the progress of the reaction was investigated by thin layer chromatography [7 liters]. After the raw materials have completely disappeared, the solution is diluted with approximately 200 g of water.
64 and separated into sediment #t-F. After drying, transfer the product to dichloromethane/! Dissolved in OCD, then Silica 3? Stirred in the presence of. The solution was filtered and concentrated under reduced pressure. To crystallize the desired product by adding hexane,
As a result, yellow crystals of itowq with a melting point of 04°C were obtained.The NMR spectrum was consistent with the structure of the desired product.6 Elemental analysis = 028H1404 Calculated value: 075.46 H4,45020,11 Observed value: 75. 57 μ, 57 19.96 Example 7 Preparation of i,r-dihy?roxyt O(J'-methoxy phenyl)-antrone a) Magnesium ramco in anhydrous THF/jd, jjV by refluxing THF in a stream of nitrogen. At the same time, 0-bromoanisole tA and coV were added. Reflux continues even after the addition is complete/
/ Lasted for J hours. Next, the obtained solution was heated at θ°C in a nitrogen stream.
l,r-dihydroxy in anhydrous THFjO-
Added drop by drop to the suspension of anthraquinone jv. After the reaction mixture was left at room temperature overnight, it was made acidic with 9 mK of glacial acetic acid and water/60% was added.
有機相を傾瀉し、水(tooaA)で2回洗った後、硫
酸マグネシウム上で乾燥させた。次に溶液を真空下にお
いて濃縮し、トルエンに溶解し7t。The organic phase was decanted, washed twice with water (tooaA) and then dried over magnesium sulphate. The solution was then concentrated under vacuum and dissolved in toluene for 7t.
この溶液t−濾過し、ヘキサンの添加により黄色沈澱j
14.これをトルエン−ヘキサン混合物から再結晶させ
た。得られた透明黄色結晶の1O−(2′−メトキシ−
フェニル)−t、I、tO−)リヒ)!ロキシアントロ
ンは融点22.0−22/cであった。This solution was filtered and a yellow precipitate formed by the addition of hexane.
14. This was recrystallized from a toluene-hexane mixture. The resulting transparent yellow crystals were 1O-(2'-methoxy-
Phenyl)-t, I, tO-)lihi)! Loxianthrone had a melting point of 22.0-22/c.
元素分析: 021 H160s
計算値: 072.40 H4,65022,97実測
値: 72.5? 4.65 25.21b)上記
a)において得られ7j / 0− (2’−メトキシ
フェニル)−t、I、tO−)リヒドロキシーアントロ
ン23flを氷酢酸90−に溶解した溶液に不活性雰囲
気中で塩化第一錫μ、り?、次に濃塩酸lμ、jdを加
えた。次に反応混合物を室温において3時間攪拌した。Elemental analysis: 021 H160s Calculated value: 072.40 H4,65022,97 Actual value: 72.5? 4.65 25.21b) A solution of 23 fl of 7j/0-(2'-methoxyphenyl)-t,I,tO-)rihydroxyanthrone obtained in a) above dissolved in 90-glacial acetic acid is placed in an inert atmosphere. Among them, tinnous chloride μ, ri? , then concentrated hydrochloric acid lμ,jd was added. The reaction mixture was then stirred at room temperature for 3 hours.
反応媒体を水200gdに注いで所期生成物を得た。シ
リカゲルクロマトグラフィーを行って純生成物/l/が
得られた。得られた黄色結晶は融点197℃であった。The reaction medium was poured into 200 gd of water to obtain the expected product. Silica gel chromatography was performed to obtain pure product/l/. The yellow crystals obtained had a melting point of 197°C.
NMRスペクトル及び質量スペクトル(m/e−iia
)は所期の生成物の構造に一致した。NMR spectrum and mass spectrum (m/e-IIA
) was consistent with the structure of the expected product.
元素分析=02.H4604
計算値: 075.89 H4,85019,25実測
値: 75.96 a、92 19.50実施例r
−アントロンの調製
a)無水エチルエーテルtoocd中のチオフェンl−
,7−の溶液に0℃、アルゴン気流中においてn−ブチ
ルリチウム10064(I,AM)を加えた。添加後、
溶液をOC,K 7時間保ち次に室温に戻しyc。Elemental analysis = 02. H4604 Calculated: 075.89 H4,85019,25 Found: 75.96 a, 92 19.50 Example r - Preparation of Anthrone a) Thiophene l- in anhydrous ethyl ether toocd
, 7- was added n-butyllithium 10064 (I, AM) at 0° C. in an argon stream. After addition,
The solution was kept at OC, K for 7 hours and then returned to room temperature.
得られた溶液を次に一71r℃、アルゴン気流中におい
て無水THFt000−中のt、I−ジヒrロキシアン
トラキノンタ、−1?の懸濁液に一滴fつ加えた。反応
混合物を室温に戻した接水酢酸jO−で酸性にした。The resulting solution was then dissolved in anhydrous THFt000-1 at -71rC under a stream of argon. One drop was added to the suspension. The reaction mixture was made acidic with aqueous acetic acid jO- which was brought to room temperature.
溶液を減圧下に濃縮した後にエチルエーテルに溶解した
。生じた褐色の沈澱を戸別した後、高温メタノール10
06dに溶解した。かぐして融点/9/−192℃の1
0−(コーチェニル)−7゜r、io−トリヒrロキシ
アントロンの黄色結晶が得られた・
元素分析:0,8H1204S
計算値: 066.65 H5,75S?、89実測値
: 66.20 5.66 9.10h)上記a)r
おいて得られた1O−(2−チェニル)−t、I、to
−)リヒドロキシアントロン5?を酢酸100cdK溶
解した溶液に不活性雰囲気中において塩化第一錫lμ、
11及び濃塩酸20dを加えた。室rI7Aにおいて2
時間攪拌した彼、溶液を水、100−へ注いだ。得られ
た生成物を戸別してから乾燥させた。かぐしてi、t−
ジヒドロキシー1O−(2−チェニル)−アントロン4
tJj?が得られ、このものはトルエンから再結晶させ
ると融点11I−/♂2℃であった。The solution was concentrated under reduced pressure and then dissolved in ethyl ether. After removing the resulting brown precipitate from house to house, add 10 liters of hot methanol.
It was dissolved in 06d. Melting point / 9 / -192℃ 1
Yellow crystals of 0-(cochenyl)-7゜r,io-trihyroxyanthrone were obtained. Elemental analysis: 0,8H1204S Calculated value: 066.65 H5,75S? , 89 Actual value: 66.20 5.66 9.10h) Above a) r
1O-(2-chenyl)-t,I,to obtained in
-) Lihydroxyanthrone 5? lμ of stannous chloride in an inert atmosphere in a solution of 100 cdK of acetic acid,
11 and 20 d of concentrated hydrochloric acid were added. 2 in chamber rI7A
After stirring for an hour, the solution was poured into 100 ml of water. The resulting product was distributed and then dried. Smell it i, t-
Dihydroxy-1O-(2-chenyl)-anthrone 4
tJj? was obtained, which had a melting point of 11I-/♂2°C when recrystallized from toluene.
NMRスペクトル及び質量スペクトル(m/e=ior
)は所期の生成物の構造に相当した。NMR spectrum and mass spectrum (m/e=ior
) corresponded to the structure of the desired product.
元素分析:0,8H1206s
計算値: 070,11 H5,92015,51S1
0,40実測値: 69.75 5,80 15.5
4 9.98実施例り
a)無水エチルエーテル1OOd中のn−ブチルリチウ
ム100J(/、sM)の溶液に一4tQ℃、不活性雰
囲気中において2−ブロムチアゾールx4′、4yを一
滴ずつ加えた。添加後反応混合物を一7r℃とし、/、
f−ジヒPロキシア°ントラキ/ン9.Af!fTHF
tOθ06/IK溶解し友ものを加えた。次に反応媒体
を室温にμg時間放置した。Elemental analysis: 0,8H1206s Calculated value: 070,11 H5,92015,51S1
0,40 Actual value: 69.75 5,80 15.5
4 9.98 Example a) To a solution of 100 J (/, sM) of n-butyllithium in 100 d of anhydrous ethyl ether at 14 tQ°C in an inert atmosphere, 2-bromothiazole x4',4y was added dropwise. . After the addition, the reaction mixture was brought to -7rC, /
9. Af! fTHF
tOθ06/IK was dissolved and added. The reaction medium was then left at room temperature for μg hours.
酢酸SO−により酸性とした後に溶液を水1000−へ
注いだ。After acidification with acetic acid SO-, the solution was poured into 1000-ml of water.
有機相を硫酸マグネシウム上で乾燥させた後に減圧下に
濃縮した。所期の生成物をシリカゲルクロマトグラフィ
ーによって精製しfc、かぐして黄色固体の形をし7j
/ 0− (J−チアゾリル)−l。The organic phase was dried over magnesium sulphate and then concentrated under reduced pressure. The desired product was purified by silica gel chromatography and smelt in the form of a yellow solid.
/0-(J-thiazolyl)-l.
t、10−)リヒドロキシアントロン3.51が得られ
・これをトルエン−ヘキサン混合物から再結晶させた。3.51 t,10-)rihydroxyanthrone was obtained which was recrystallized from a toluene-hexane mixture.
結晶の融点は223−22j℃であった。The melting point of the crystals was 223-22j°C.
NMRスペクトルならびに質量スペクトル(r、+7.
=i 2 s )は所期の生成物の構造に一致した。NMR spectrum and mass spectrum (r, +7.
= i 2 s ) was consistent with the structure of the expected product.
元素分析=01.H11NO4S
計算値=062・76 H5,41019,67N4.
5OS9.86実測値: 62.85 3,41 1
9.65 4.59 9.66b)上記a)において得
られたtO−(J−チアゾリル)−1,1llO−トリ
ヒPロキシアントロンコVの酢酸75d中の懸濁液に、
金属錫2?と塩酸コjcPIとを加え−yca混合物を
水浴上で1時間加熱し、原料化合物を完全に溶解させた
。水コ00(dへ注ぎ、得られた生成物tF別した。か
ぐしてi、1−ジヒドロキシー1O−(J−チアゾリル
)−アントロン/lFi得、これをメ、タノールから再
結晶−させた。再結晶させた生成物の融点はl42℃で
ある。Elemental analysis = 01. H11NO4S Calculated value = 062・76 H5, 41019, 67N4.
5OS9.86 Actual value: 62.85 3,41 1
9.65 4.59 9.66b) To a suspension of tO-(J-thiazolyl)-1,1llO-trihyproxyantronchoV obtained in a) above in 75d of acetic acid,
Metal tin 2? and hydrochloric acid cojcPI, and the -yca mixture was heated on a water bath for 1 hour to completely dissolve the starting compounds. The obtained product was separated by tF. It was sifted to obtain i,1-dihydroxy-1O-(J-thiazolyl)-anthrone/lFi, which was recrystallized from methanol. The melting point of the recrystallized product is 142°C.
元素分析: 017H,、N O68
計算値: (H66,0n HA、58 N4.520
15.51 510j5実測値: 66.15 5.
60 4.60 15.92 10.15実施例10
磁気攪拌機と窒素送入口とを備えた三つロフラスコ中に
おいて無水酢酸jd中の実施例jに従って得られ[/
0− (j’−メトキシ−フェニル)−1,r−ジヒP
ロキシアンドロンλ00q及び数滴のピリジンを攪拌し
た。混合物をIOcにおいて3時間攪拌した後に冷却さ
せた。所期のトリエステルが結晶化し、その液を切9次
にヘキサンで洗浄した。融点27t℃の黄色透明の結晶
is。Elemental analysis: 017H,, NO68 Calculated value: (H66,0n HA, 58 N4.520
15.51 510j5 Actual value: 66.15 5.
[/
0-(j'-methoxy-phenyl)-1,r-dihyP
Stir in Roxiandrone λ00q and a few drops of pyridine. The mixture was stirred for 3 hours at IOc and then allowed to cool. The desired triester crystallized and the solution was cut and washed with hexane. It is a yellow transparent crystal with a melting point of 27t°C.
キが得られた。I got the key.
元素分析: C27H2207
計算値: 070.75 H4,84C24,as実測
値: 70.47 s、C124,24実施例//
l O−(j’−メトキシ−フェニル) −/ * l
!*り磁気攪拌機を備えた三つロフラスコ中において実
施例!に従って得られ7’C/ 0− (j’−メトキ
シフェニル)−t、I−ジヒドロキシ アントロン45
0〜を無水プロピオン酸s cj K溶解したものと数
滴のピリジンとを攪拌した。混合物を不活性雰囲気中、
to’6rcおいて6時間攪拌した。Elemental analysis: C27H2207 Calculated value: 070.75 H4,84C24,as Actual value: 70.47 s, C124,24 Example // l O-(j'-methoxy-phenyl) -/ * l
! *Example carried out in a three-hole flask equipped with a magnetic stirrer! 7′C/0-(j′-methoxyphenyl)-t,I-dihydroxy anthrone 45 obtained according to
A solution of propionic anhydride scj K and several drops of pyridine were stirred. the mixture in an inert atmosphere,
The mixture was stirred at 6rc for 6 hours.
溶液を水100−へ注ぎ、エーテルで抽出した後に炭酸
水素ナトリウム水溶液で洗浄した。次に硫酸マグネシウ
ム上で乾燥させた後(減圧下で濃縮した。ヘキサンの添
加により所期のトリエステル200qを単離した。The solution was poured into 100ml of water, extracted with ether, and washed with an aqueous sodium bicarbonate solution. After drying over magnesium sulfate (concentration under reduced pressure), 200q of the expected triester was isolated by addition of hexane.
得られた黄色結晶は融点t77−t71℃であつ[、N
MRスペクトル及び質量分析(m/e=200)は所期
の生成物の構造に相当した。The yellow crystals obtained had a melting point of t77-t71°C [,N
MR spectrum and mass spectrometry (m/e=200) corresponded to the structure of the expected product.
実施例1λ
セトキシ アントラセンの調製
磁気攪拌機を備えた三つロフラスコ中において、実施例
IK従って得られた1o−(コーチェニル)−t、r−
ジヒドロキシ アントロン全同価岬を無水酢酸jcnに
溶解したものと数滴のピリジンとを攪拌した。混合物を
不活性雰囲気中、10℃において3時間攪拌した後冷却
させ友。所期のトリエステルが沈澱し、これを次に液を
切9ヘキサンで洗浄した。か(して融点it、0℃の黄
色う明の結晶300〜が得られた。Example 1 Preparation of λ Setoxy Anthracene In a three-necked flask equipped with a magnetic stirrer, 1o-(cochenyl)-t,r- obtained according to Example IK
A solution of dihydroxy anthrone total isovalent cape in acetic anhydride jcn and a few drops of pyridine were stirred. The mixture was stirred for 3 hours at 10° C. in an inert atmosphere and then cooled. The desired triester precipitated, which was then drained and washed with 9 hexane. As a result, yellowish crystals with a melting point of 0° C. were obtained.
元素分析: C24H180b ”
計算値: 066.55 H4,17022,1087
,58実測値: 66.55 4.19 22,20
7.26実施例13
パノイルオキシーアントラセンの調製
磁気攪拌機を備えた三つロフラスコ中において、実施例
tlC従って得られたtO−(コーチェニル)−i、!
−ジヒ)Iロキシ アントロン+25OI#Iを無水プ
ロピオン酸s cd K溶解し友ものと数滴のピリジン
とを攪拌した。混合物全窒素気流中tO℃において6時
間攪拌した。冷却により所期の生成物を沈澱させた。黄
色結晶/JOayt−単離した。Elemental analysis: C24H180b” Calculated value: 066.55 H4,17022,1087
,58 actual measurement value: 66.55 4.19 22,20
7.26 Example 13 Preparation of panoyloxy-anthracene In a three-necked flask equipped with a magnetic stirrer, tO-(cochenyl)-i,! obtained according to Example tlC!
- Dihi) I Roxy Anthrone + 25OI #I was dissolved in propionic anhydride scd K, and the mixture and several drops of pyridine were stirred. The mixture was stirred for 6 hours at tO 0 C in a stream of total nitrogen. The desired product precipitated on cooling. Yellow crystals/JOayt-isolated.
P液を水ioo、、4へ注ぎ、エーテルで抽出し炭酸水
素ナトリウム水溶液で洗浄し友後エーテル相を乾燥させ
、減圧下に濃縮し友。残渣にヘキサンを添加して補足分
の、所期のトリエステル/jOqを得た。黄色透明の結
晶は融点t 92Cでめった。The P solution was poured into water, extracted with ether, washed with an aqueous sodium bicarbonate solution, and the ether phase was dried and concentrated under reduced pressure. Hexane was added to the residue to obtain a supplementary portion of the desired triester/jOq. Clear yellow crystals were formed with a melting point of t 92C.
NMRスペクトル及び質量スペクトル(m/ e =4
t76)は所期の生成物の構造に相当した。NMR spectrum and mass spectrum (m/e = 4
t76) corresponded to the structure of the expected product.
実施例ta
無水トルエンizo、4中の70− (2’−チェニル
)−i、r−)ヒrロキシアントロン2vの溶液を室温
において光線と空気中の水分とを遮断して攪拌しながら
これに5モル当量のピリジンをまたすぐ続いて5モル当
量のピパノイルククライドを加えた。次に反応混合物を
1時間還流冷却しながら加熱し7’Caこの時間の終9
には原料化合物は完全に転化していた。Example ta A solution of 2v of 70-(2'-chenyl)-i,r-)hyroxyantrone in anhydrous toluene, izo, 4, was added to it at room temperature with stirring, shielded from light and moisture in the air. Five molar equivalents of pyridine were also added immediately followed by five molar equivalents of pipenoyl cucide. The reaction mixture was then heated with reflux cooling for 1 hour and at the end of this time 9
The starting compounds were completely converted.
次に反応媒体を減圧下に濃縮し水に溶解し、塩化メチレ
ンで抽出した。The reaction medium was then concentrated under reduced pressure, dissolved in water and extracted with methylene chloride.
塩化メチレン相を水で洗い傾瀉し、硫酸マグネシウム上
で乾燥させ濃縮した。The methylene chloride phase was washed with water, decanted, dried over magnesium sulfate and concentrated.
得られた固体をヘキサン−酢酸エチル混合物から再結晶
させた。融点/70℃の黄色結晶t、ztが得られた。The resulting solid was recrystallized from a hexane-ethyl acetate mixture. Yellow crystals t, zt with a melting point of 70°C were obtained.
NMRスペクトル及び質量スペクトル(m/e=<C7
6)Fi所期の生成物の構造に相当した。NMR spectrum and mass spectrum (m/e=<C7
6) Fi corresponded to the structure of the expected product.
実施例I
粉末0.19人のゼラチンカプセル
ゼラチン、二酸化チタン及び防腐剤からなるゼラチンカ
プセルにより下記の粉末o、zrit−包装した:
/、lj−ジヒドロキシ−10−(λ′−メトキシーフ
ェニル)−アントロン 0.39馬鈴薯澱粉
(27Pラクトースを加え
て 0.!V実施例■
下記成分の混合物・からljの錠剤を調製した:t、r
−ジヒドロキシー10−(2−
チェニル)−アントロン o、tty
ポリビニルピロリrン 0.0
/ j P架橋ポリビニルピロリPン 0
,01 9タルク o
、or vD蔚USSA社から市販のシリカ
Aerosil 200” 0.
00 t ?ラクトースを加えて
too vこの例において1.t−ジヒドロキシー1
O−(2−チェニル)アントロン全同価の量のt、1−
ジヒドロキシ−t O−(j’−メトキシフェニル)−
アントロンで代替できる。Example I Powder 0.19 Gelatin Capsules The following powders were packaged in gelatin capsules consisting of gelatin, titanium dioxide and preservatives: /, lj-dihydroxy-10-(λ'-methoxyphenyl)- Anthrone 0.39 potato starch
(By adding 27P lactose 0.!V Example■ lj tablets were prepared from a mixture of the following ingredients: t, r
-dihydroxy-10-(2-chenyl)-anthrone o, tty
Polyvinyl pyrroline 0.0
/ j P crosslinked polyvinylpyrroli Pn 0
,01 9 talc o
Aerosil 200"0.0" silica commercially available from , or vD USSA, Inc.
00t? add lactose
too v In this example 1. t-dihydroxyl 1
O-(2-chenyl)anthrone total equivalent amount t, 1-
Dihydroxy-t O-(j'-methoxyphenyl)-
Can be replaced with Antron.
実施例■
使用直前に下記組成の粉末jOffを、ミネラルウォー
ター60−に攪拌混合しfc=
/、r−ジヒ?oキ’/ −t O’ −(j’ −ヒ
ドロキシフェニル)−アントロン o、ttt安
息香酸ナトリウム o、ist塩化
ナトリウム 0.2J?無水
(えん酸ナトリウム /、/1クリシル
リジン酸アンモニウム 0.06?香料所
要鎗
着色料 所要針
サッカロースを加えて JOf一旦調
製したシロップは冷所に貯蔵することを必要とするその
安定性は7日以内である。Example ■ Immediately before use, powder jOff with the following composition was stirred and mixed into mineral water 60-60-100 ml. oki'/ -t O'-(j' -hydroxyphenyl)-anthrone o, ttt Sodium benzoate o, ist Sodium chloride 0.2J? Anhydrous (sodium citrate /, /1 ammonium chrysylrizinate 0.06? Flavoring required) Colorant required Adding saccharose Once prepared, the syrup needs to be stored in a cool place. Its stability is within 7 days. It is.
実施例■
/、J’−ジヒドo 4 シー / 0− (3’ −
ヒドロキシフェニル)−アントロン tyDEf
lUSSA社から市販のシリカ
−Aerosil 200−
7 tミリスチン酸インプロピルを加えて 100
?実施例■
i、r−ジヒドロキシ−t o −(2′−メトキシフ
ェニル)アントロン /、4 pセレシン
tr yワセリン油
3j Vワセリンを加えて
ioo yとの例においては1
.r−ジヒドロキシー1O−(2′−メトキシフェニル
)−アントロンヲ同価の量のt、r−ジヒドロキシ−7
0−(J’−メトキシフェニル)アントロンにより代替
できる。Example ■ /, J'-dihydro 4 C / 0- (3'-
hydroxyphenyl)-anthrone tyDEf
Commercially available silica - Aerosil 200 - from USSA
Add 7t inpropyl myristate 100
? Example ■ i, r-dihydroxy-t o -(2'-methoxyphenyl) anthrone /, 4 p ceresin
Try vaseline oil
3j V Add Vaseline In the example with ioo y, 1
.. r-dihydroxy-1O-(2'-methoxyphenyl)-anthrone and an equivalent amount of t,r-dihydroxy-7
It can be replaced by 0-(J'-methoxyphenyl)anthrone.
実施例■
t、f−ジヒrロキシー1O−(2−チェニル)−アン
トロン t3fミリスチン
酸イソプロピル J AJ Pシリコーン
油(几HONE POULENO社から几HonoFL
su、 u 7 V 、? o o o名称テ市販のジ
メチルポリシロキサン)36.μV蜜蝋
/j、t?シリコーン油、GOL
DS I OHMI DT社から−ABIL j 00
000 cal″’o名称テ市販のもの、を加えて
100 r実施例U
その場で混合するためのニ シャン −、 a)懸濁
液の形の処理用液体
i、r−ジヒrロキシー1O−(3′
メトキシ−フェニル)アントロン o、s ti
ワセリン油を加えて too t2°
)洗浄用液体
3.5モル−ポリグリセa−ル化
したPデカンジオール λor下記の式
の化合物: /、71?RR
(ただしR=(IH、x+y−7及びnニアo)水を加
えて 100 f処理用液体
をはげしく攪拌した後に適用瓶において洗浄用液体とl
θ/ 5’ 0の比率で混合する。Example ■ t,f-DihydroxylO-(2-thenyl)-anthrone t3f Isopropyl myristate J AJ P silicone oil (HonoFL from HONE POULENO)
su, u 7 V,? o o o Name (commercially available dimethylpolysiloxane) 36. μV beeswax
/j,t? silicone oil, GOL
DS I OHMI From DT Company-ABIL j 00
Add 000 cal'''o name and commercially available
100 rExample U Nishan-, a) Processing liquid in the form of suspension i, r-dihyrroxy 1O-(3' methoxy-phenyl) anthrone o, s ti
Add Vaseline oil too t2°
) Cleaning liquid 3.5 mol - polyglycerated P-decanediol λor compound of the following formula: /, 71? RR (where R = (IH,
Mix at a ratio of θ/5'0.
一旦調製した混合物はただちに使用することが必要であ
る。Once the mixture has been prepared, it is necessary to use it immediately.
実施例■
ラノリン酸マグネシウム j、41ラ
ノ1リンアルコール λ、tVペ
ルヒドロヌクワレン 20 Pミリ
スチン酸インプロピル st純ごま油
10 ?ワセリン油
r、itサリチル酸
l ?tO−<X−チェニル)−1
,ざ、タートリプロバノイルオキシアントラセン
/?p−ヒトaオキシ安息香酸メチル 0.3I
P水を加えて too f
実施例■
脱毛−ふけ防止毛髪用組成物
/ 0− (j’−メトキシ−フェニル)−t、r、デ
ートリアセトキシ−アント
ラセン o、、rti
サリチルfil O
,/f?サリチル酸ベンジルを加えて too
y実施例X
lIr−ジビノ々ロイルオキシ−i。Example ■ Magnesium lanophosphate j, 41 lano-1 phosphate alcohol λ, tV perhydronuqualene 20 P inpropyl myristate st pure sesame oil
10? vaseline oil
r,it salicylic acid
l? tO-<X-chenyl)-1
, tertriprobanoyloxyanthracene
/? Methyl p-human aoxybenzoate 0.3I
P Add water too f
Example ■ Hair removal-anti-dandruff hair composition/0-(j'-methoxy-phenyl)-t,r,dateriacetoxy-anthracene o,,rti
salicyl fil O
,/f? Add benzyl salicylate too
y Example X lIr-divinoroyloxy-i.
−(2−チェニル)アントロン o、rv塩化
第一錫 0.3?ミリス
チ/酸インプロピルを加えて too y実施
例X
ブチルヒPロキシトルエン20qを含有するりj0エタ
ノールtOdと4リエチレン/’ IJ コ−ル(PE
G)goo 30.Illとからなる溶液に/、r−
ピノクロイルオキシ−10−(2−fエニル)アントロ
ンO,コfを加え7′c。-(2-chenyl)anthrone o, rv stannous chloride 0.3? Example
G) goo 30. In a solution consisting of Ill/, r-
Add pinochloroyloxy-10-(2-fenyl)anthrone O, cof and 7'c.
攪拌溶解後にこのローションを毛髪全体に適用する。After stirring and dissolving, apply this lotion all over the hair.
望ましくはこの処置を1日2回行なうべきである。Preferably this treatment should be performed twice a day.
Claims (1)
i)▲数式、化学式、表等があります▼ (式中、R_1、R_2、R_3、R_4及びR_5は
同一であるか又は異なるものであつてかつ水素原子、ハ
ロゲン原子、CF_3基、ヒドロキシル基、低級アルキ
ル基、低級シクロアルキル基、低級ヒドロキシアルキル
基、低級アルコキシ基、ニトリル基 ▲数式、化学式、表等があります▼、▲数式、化学式、
表等があります▼、▲数式、化学式、表等があります▼
、 ▲数式、化学式、表等があります▼、−(CH_2)_
n−CO_2R′又は▲数式、化学式、表等があります
▼の基を表わし、r′及びr″は同一であるか又は異な
るものであつてかつ水素原子又は低級アルキル基を表わ
し、nは0又は1、2又は3の整数であり、R′及びR
″は水素原子、直鎖又は分岐鎖低級アルキル基又はアリ
ール基であつてかつ場合により置換基を有するものを表
わすが、但し、R_1乃至R_5のうちの少なくとも一
個は水素原子でないものとする) (ii) ▲数式、化学式、表等があります▼ (iii) ▲数式、化学式、表等があります▼ (両式中、R_6はR_1乃至R_5基について示した
定義のうちの一つを有する)及び (iv) ▲数式、化学式、表等があります▼ のうちの一つで示される芳香族残基を表わす〕で表わさ
れる、10−アリール−1,8−ジヒドロキシアントロ
ン、又は、そのモノ−、ジ−又はトリエステル。 2、Ar基が式: ▲数式、化学式、表等があります▼ (式中R_1(又はR_5)は低級アルコキシ基又は式
:▲数式、化学式、表等があります▼の基を表わし、R
′は炭素数1乃至5個の直鎖又は分岐鎖アルキル基を表
わし、R″は水素原子を表わし、R_3は水素原子又は
低級アルコキシ基を表わし、R_2、R_4及びR_5
(又はR_1)は水素原子を表わす)で示される芳香族
残基を表わす、特許請求の範囲第1項記載の化合物。 3、Ar基が式: ▲数式、化学式、表等があります▼ (式中、R_2(又はR_4)は−CF_3基、低級ア
ルコキシ基又はヒドロキシル基を表わし、R_1、R_
3、R_4(又はR_2)及びR_5は水素原子を表わ
す)で示される芳香族残基を表わす、特許請求の範囲第
1項記載の化合物。 4、Ar基は式: ▲数式、化学式、表等があります▼ (式中、R_3は低級アルコキシ基を表わし、R_1、
R_2、R_4、R_5は水素原子を表わす)で示され
る芳香族残基を表わす、特許請求の範囲第1項記載の化
合物。 5、1,8−ジヒドロキシ−10−〔2′−(N−2″
,2″−ジメチルプロパノイル)アミノフエニル〕−ア
ントロン、1,8−ジヒドロキシ−10−(2′,4′
−ジメトキシフエニル)−アントロン、1,8−ジヒド
ロキシ−10−(4′−メトキシフエニル)−アントロ
ン、1,8−ジヒドロキシ−10−(3′−トリフルオ
ルメチルフエニル)−アントロン、1,8−ジヒドロキ
シ−10−(3′−メトキシフエニル)−アントロン、
1,8−ジヒドロキシ−10−(3′−ヒドロキシフエ
ニル)−アントロン、1,8−ジヒドロキシ−10−(
2′−メトキシフエニル)−アントロン、1,8−ジヒ
ドロキシ−10−(2−チエニル)−アントロンおよび
1,8−ジヒドロキシ−10−(2−チアゾリル)−ア
ントロンからなる群から選ばれる、特許請求の範囲第1
項乃至第4項のいずれかに記載の化合物。 6、式( I )の化合物のモノ−、ジ−及びトリエステ
ルは、下記の一般式(II): ▲数式、化学式、表等があります▼(II) (式中Arは特許請求の範囲第1項において定義したも
のと同一の意義を有するものであり、pは0又は1であ
り、p=0のときR_6は水素原子又は−COR_1_
0基を表わし、R_9は−COR_1_0基を表わしそ
してp′は1であり;P=1のときi)R_7は水素原
子を表わし、R_8は水素原子又は−COR_1_0基
を表わし、R_9は−COR_1_0基を表わしそして
p′は0であるかまたはii)R_7は−COR_1_
0基を表わしR_8及びR_9は−COR_1_0基を
表わしそしてp′は0であり;R_1_0は炭素数1乃
至10個の直鎖又は分岐鎖アルキル基、シクロアルキル
基、2−ピリジル基、2−チエニル基又はフエニル基で
あつてかつ場合により、低級アルキル基、低級アルコキ
シ基、ハロゲン原子、ニトロ基、 −CF_3基又はヒドロキシル基により置換されている
ものを表わす)で表わされる、特許請求の範囲第1項記
載の化合物またはその混合物。 7、10−(3′−メトキシフエニル)−1,8,9−
トリアセトキシアントラセン、10−(3′−メトキシ
フエニル)−1,8,9−トリプロパノイルオキシアン
トラセン、10−(2−チエニル)−1,8,9−トリ
アセトキシアントラセン、10−(2−チエニル)−1
,8,9−トリプロパノイルオキシアントラセン、10
−(2−チエニル)−1,8−ジピバノイルオキシアン
トラセンからなる群から選ばれる、特許請求の範囲第6
項記載の化合物。 8、1)1,8−ジヒドロキシアントラキノンに無水溶
剤媒体中で少なくとも4モル当量の芳香族リチウム化合
物(ArLi)を反応させ、酸性化した後に、生成した
10−アリール−1,8,10−トリヒドロキシアント
ロンを単離する工程及び2)10−アリール−1,8,
10−トリ ヒドロキシアントロンを酢酸媒体中で、塩化第一錫又は
金属錫及び濃塩酸の存在下において還元し、ついで10
−アリール−1,8−ジヒドロキシアントロンを水中で
沈澱させて単離し、必要に応じ、エステル化する工程;
を行うことを特徴とする、一般式( I ): ▲数式、化学式、表等があります▼( I ) 〔式中Arは下記の式(i)〜(iv):すなわち、(
i)▲数式、化学式、表等があります▼ (式中、R_1、R_2、R_3、R_4及びR_5は
同一であるか又は異なるものであつてかつ水素原子、ハ
ロゲン原子、CF_3基、ヒドロキシル基、低級アルキ
ル基、低級シクロアルキル基、低級ヒドロキシアルキル
基、低級アルコキシ基、ニトリル基 ▲数式、化学式、表等があります▼、▲数式、化学式、
表等があります▼、▲数式、化学式、表等があります▼
、 ▲数式、化学式、表等があります▼、−(CH_2)_
n−CO_2R′又は▲数式、化学式、表等があります
▼の基を表わし、r′及びr″は同一であるか又は異な
るものであつてかつ水素原子又は低級アルキル基を表わ
し、nは0又は1、2又は3の整数であり、R′及びR
″は水素原子、直鎖又は分岐鎖低級アルキル基又はアリ
ール基であつてかつ場合により置換基を有するものを表
わすが、但し、R_1乃至R_5のうちの少なくとも一
個は水素原子でないものとする) (ii) ▲数式、化学式、表等があります▼ (iii) ▲数式、化学式、表等があります▼ (両式中、R_6はR_1乃至R_5基について示した
定義のうちの一つを有する)及び (iv) ▲数式、化学式、表等があります▼ のうちの一つで示される芳香族残基を表わす〕で表わさ
れる10−アリール−1,8−ジヒドロキシアントロン
、又は、そのモノ−、ジ−又はトリエステルの製造方法
。 9、第1工程はエテルエーテル又はテトラヒドロフラン
中、−80乃至0℃の温度において30分乃至2時間実
施する、特許請求の範囲第7項記載の方法。 10、第2工程は室温において0.5乃至5時間実施す
る、特許請求の範囲第7項記載の方法。 11、有効成分として、一般式( I ): ▲数式、化学式、表等があります▼( I ) 〔式中Arは下記の式(i)〜(iv):すなわち、(
i) ▲数式、化学式、表等があります▼ (式中、R_1、R_2、R_3、R_4及びR_5は
同一であるか又は異なるものであつてかつ水素原子、ハ
ロゲン原子、CF_3基、ヒドロキシル基、低級アルキ
ル基、低級シクロアルキル基、低級ヒドロキシアルキル
基、低級アルコキシ基、ニトリル基 ▲数式、化学式、表等があります▼、▲数式、化学式、
表等があります▼、▲数式、化学式、表等があります▼
、 ▲数式、化学式、表等があります▼、−(CH_2)_
n−CO_2R′又は▲数式、化学式、表等があります
▼の基を表わし、r′及びr″は同一であるか又は異な
るものであつてかつ水素原子又は低級アルキル基を表わ
し、nは0又は1、2又は3の整数であり、R′及びR
″は水素原子、直鎖又は分岐鎖低級アルキル基又はアリ
ール基であつてかつ場合により置換基を有するものを表
わすが、但し、R_1乃至R_5のうちの少なくとも一
個は水素原子でないものとする) (ii) ▲数式、化学式、表等があります▼ (iii) ▲数式、化学式、表等があります▼ (両式中、R_6はR_1乃至R_5基について示した
定義のうちの一つを有する)及び (iv) ▲数式、化学式、表等があります▼ のうちの一つで示される芳香族残基を表わす〕で表わさ
れる、10−アリール−1,8−ジヒドロキシアントロ
ン、又は、そのモノ−、ジ−又はトリエステルの少なく
とも1種を含有してなる、医薬又は化粧料組成物。 12、有効成分を組成物の全重量に基いて、0.005
乃至70重量%の濃度で含有する、特許請求の範囲第1
1項記載の組成物。[Claims] 1. General formula (I): ▲There are mathematical formulas, chemical formulas, tables, etc.▼(I) [In the formula, Ar represents the following formulas (i) to (iv): That is, (
i) ▲There are mathematical formulas, chemical formulas, tables, etc.▼ (In the formula, R_1, R_2, R_3, R_4 and R_5 are the same or different and are hydrogen atoms, halogen atoms, CF_3 groups, hydroxyl groups, lower Alkyl group, lower cycloalkyl group, lower hydroxyalkyl group, lower alkoxy group, nitrile group
There are tables, etc. ▼, ▲ There are mathematical formulas, chemical formulas, tables, etc. ▼
, ▲There are mathematical formulas, chemical formulas, tables, etc.▼, -(CH_2)_
n-CO_2R' or ▲There are mathematical formulas, chemical formulas, tables, etc.▼ group, r' and r'' are the same or different and represent a hydrogen atom or a lower alkyl group, and n is 0 or is an integer of 1, 2 or 3, R' and R
'' represents a hydrogen atom, a linear or branched lower alkyl group, or an aryl group, and optionally has a substituent, provided that at least one of R_1 to R_5 is not a hydrogen atom) ( ii) ▲There are mathematical formulas, chemical formulas, tables, etc.▼ (iii) ▲There are mathematical formulas, chemical formulas, tables, etc.▼ (In both formulas, R_6 has one of the definitions shown for the R_1 to R_5 groups) and ( iv) 10-aryl-1,8-dihydroxyanthrone, or its mono- or di- or triester. 2. Ar group is a formula: ▲There are mathematical formulas, chemical formulas, tables, etc.▼ (In the formula, R_1 (or R_5) represents a lower alkoxy group or a group of the formula: ▲There are mathematical formulas, chemical formulas, tables, etc.▼ ,R
' represents a straight or branched alkyl group having 1 to 5 carbon atoms, R'' represents a hydrogen atom, R_3 represents a hydrogen atom or a lower alkoxy group, R_2, R_4 and R_5
The compound according to claim 1, which represents an aromatic residue represented by (or R_1) represents a hydrogen atom. 3. Ar group is a formula: ▲ There are mathematical formulas, chemical formulas, tables, etc. ▼ (In the formula, R_2 (or R_4) represents -CF_3 group, lower alkoxy group or hydroxyl group, R_1, R_
3. The compound according to claim 1, which represents an aromatic residue represented by R_4 (or R_2) and R_5 each represent a hydrogen atom. 4. The Ar group has the formula: ▲There are mathematical formulas, chemical formulas, tables, etc.▼ (In the formula, R_3 represents a lower alkoxy group, R_1,
The compound according to claim 1, which represents an aromatic residue represented by R_2, R_4, R_5 each represents a hydrogen atom. 5,1,8-dihydroxy-10-[2'-(N-2''
, 2″-dimethylpropanoyl)aminophenyl]-anthrone, 1,8-dihydroxy-10-(2′,4′
-dimethoxyphenyl)-anthrone, 1,8-dihydroxy-10-(4'-methoxyphenyl)-anthrone, 1,8-dihydroxy-10-(3'-trifluoromethylphenyl)-anthrone, 1, 8-dihydroxy-10-(3'-methoxyphenyl)-anthrone,
1,8-dihydroxy-10-(3'-hydroxyphenyl)-anthrone, 1,8-dihydroxy-10-(
Claims selected from the group consisting of 2'-methoxyphenyl)-anthrone, 1,8-dihydroxy-10-(2-thienyl)-anthrone and 1,8-dihydroxy-10-(2-thiazolyl)-anthrone. range 1
A compound according to any one of Items 1 to 4. 6. Mono-, di- and triesters of the compound of formula (I) are represented by the following general formula (II): ▲There are mathematical formulas, chemical formulas, tables, etc.▼(II) (Ar in the formula It has the same meaning as defined in Section 1, p is 0 or 1, and when p = 0, R_6 is a hydrogen atom or -COR_1_
0 group, R_9 represents a -COR_1_0 group, and p' is 1; when P=1 i) R_7 represents a hydrogen atom, R_8 represents a hydrogen atom or a -COR_1_0 group, and R_9 represents a -COR_1_0 group; and p' is 0 or ii) R_7 is -COR_1_
R_8 and R_9 represent -COR_1_0 groups, and p' is 0; R_1_0 is a straight or branched alkyl group having 1 to 10 carbon atoms, a cycloalkyl group, a 2-pyridyl group, a 2-thienyl group. or a phenyl group optionally substituted with a lower alkyl group, a lower alkoxy group, a halogen atom, a nitro group, a -CF_3 group, or a hydroxyl group), Claim 1 Compounds or mixtures thereof as described in Section. 7,10-(3'-methoxyphenyl)-1,8,9-
Triacetoxyanthracene, 10-(3'-methoxyphenyl)-1,8,9-tripropanoyloxyanthracene, 10-(2-thienyl)-1,8,9-triacetoxyanthracene, 10-(2- thienyl)-1
,8,9-tripropanoyloxyanthracene, 10
-(2-thienyl)-1,8-dipibanoyloxyanthracene
Compounds described in Section. 8,1) After reacting 1,8-dihydroxyanthraquinone with at least 4 molar equivalents of an aromatic lithium compound (ArLi) in an anhydrous solvent medium and acidifying the resulting 10-aryl-1,8,10-tri Step of isolating hydroxyanthrone and 2) 10-aryl-1,8,
10-trihydroxyanthrone is reduced in acetic acid medium in the presence of stannous chloride or metallic tin and concentrated hydrochloric acid, then 10
- isolating the aryl-1,8-dihydroxyanthrone by precipitation in water and optionally esterifying it;
General formula (I): ▲There are mathematical formulas, chemical formulas, tables, etc.▼(I)
i) ▲There are mathematical formulas, chemical formulas, tables, etc.▼ (In the formula, R_1, R_2, R_3, R_4 and R_5 are the same or different and are hydrogen atoms, halogen atoms, CF_3 groups, hydroxyl groups, lower Alkyl group, lower cycloalkyl group, lower hydroxyalkyl group, lower alkoxy group, nitrile group
There are tables, etc. ▼, ▲ There are mathematical formulas, chemical formulas, tables, etc. ▼
, ▲There are mathematical formulas, chemical formulas, tables, etc.▼, -(CH_2)_
n-CO_2R' or ▲There are mathematical formulas, chemical formulas, tables, etc.▼ group, r' and r'' are the same or different and represent a hydrogen atom or a lower alkyl group, and n is 0 or is an integer of 1, 2 or 3, R' and R
'' represents a hydrogen atom, a linear or branched lower alkyl group, or an aryl group, and optionally has a substituent, provided that at least one of R_1 to R_5 is not a hydrogen atom) ( ii) ▲There are mathematical formulas, chemical formulas, tables, etc.▼ (iii) ▲There are mathematical formulas, chemical formulas, tables, etc.▼ (In both formulas, R_6 has one of the definitions shown for the R_1 to R_5 groups) and ( iv) 10-aryl-1,8-dihydroxyanthrone, or its mono-, di- or Method for producing triester. 9. The method according to claim 7, wherein the first step is carried out in ether ether or tetrahydrofuran at a temperature of -80 to 0° C. for 30 minutes to 2 hours. 10. Second step The method according to claim 7, wherein the method is carried out at room temperature for 0.5 to 5 hours. 11. As an active ingredient, the general formula (I): ▲There are mathematical formulas, chemical formulas, tables, etc. The middle Ar is represented by the following formulas (i) to (iv): that is, (
i) ▲There are mathematical formulas, chemical formulas, tables, etc.▼ (In the formula, R_1, R_2, R_3, R_4 and R_5 are the same or different and are hydrogen atoms, halogen atoms, CF_3 groups, hydroxyl groups, lower Alkyl group, lower cycloalkyl group, lower hydroxyalkyl group, lower alkoxy group, nitrile group
There are tables, etc. ▼, ▲ There are mathematical formulas, chemical formulas, tables, etc. ▼
, ▲There are mathematical formulas, chemical formulas, tables, etc.▼, -(CH_2)_
n-CO_2R' or ▲There are mathematical formulas, chemical formulas, tables, etc.▼ group, r' and r'' are the same or different and represent a hydrogen atom or a lower alkyl group, and n is 0 or is an integer of 1, 2 or 3, R' and R
'' represents a hydrogen atom, a linear or branched lower alkyl group, or an aryl group, and optionally has a substituent, provided that at least one of R_1 to R_5 is not a hydrogen atom) ( ii) ▲There are mathematical formulas, chemical formulas, tables, etc.▼ (iii) ▲There are mathematical formulas, chemical formulas, tables, etc.▼ (In both formulas, R_6 has one of the definitions shown for the R_1 to R_5 groups) and ( iv) 10-aryl-1,8-dihydroxyanthrone, or its mono- or di- or a triester. 12. Based on the total weight of the composition, the active ingredient is 0.005
Claim 1 containing at a concentration of 70% by weight
Composition according to item 1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR8409203A FR2565966B1 (en) | 1984-06-13 | 1984-06-13 | ARYL-10 DIHYDROXY-1,8 ANTHRONES AND THEIR ESTERS, THEIR PREPARATION PROCESS AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS |
FR8409203 | 1984-06-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS6140238A true JPS6140238A (en) | 1986-02-26 |
Family
ID=9304944
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP12639185A Pending JPS6140238A (en) | 1984-06-13 | 1985-06-12 | 10_aryl_1,8_dihydroxyanthrone, manufacture and medicinal or cosmetic composition |
Country Status (11)
Country | Link |
---|---|
JP (1) | JPS6140238A (en) |
BE (1) | BE902642A (en) |
CA (1) | CA1253859A (en) |
CH (1) | CH664557A5 (en) |
DE (1) | DE3521074A1 (en) |
DK (1) | DK265185A (en) |
FR (1) | FR2565966B1 (en) |
GB (1) | GB2160864B (en) |
IT (1) | IT1190365B (en) |
NL (1) | NL8501699A (en) |
SE (1) | SE459807B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4843097A (en) * | 1984-06-13 | 1989-06-27 | Groupement D'interet Economique Dit: Centre International De Recherches Dermatologiques C.I.R.D. | 10-aryl-1,8-dihydroxy-9-anthrones and their esters, process for preparing same, and use of same in human and veterinary medicine and in cosmetics |
DE4231636A1 (en) * | 1992-09-22 | 1994-03-24 | Beiersdorf Ag | New anthrone and anthracene derivatives substituted in the 10-position, processes for their preparation, pharmaceutical or cosmetic compositions containing these compounds and their use |
US5426197A (en) * | 1993-07-19 | 1995-06-20 | Teva Pharmaceutical Industries, Ltd. | 10-substituted 1,8-dihydroxy-9(10H) anthracenone pharmaceuticals |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL31289A (en) * | 1968-01-08 | 1974-01-14 | Ciba Geigy Ag | Pharmaceutical preparation containing a dermatologically active difluorinated corticoid and dithranol |
DE2154608A1 (en) * | 1970-11-12 | 1972-06-29 | Ciba-Geigy Ag, Basel (Schweiz) | New diacetate, pharmaceutical preparations and manufacturing processes |
DE3002089A1 (en) * | 1980-01-22 | 1981-07-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | NEW, SUBSTITUTED 1,8-DIHYDROXY-9- (10H) -ANTHRACENONE, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
FR2492372A1 (en) * | 1980-10-21 | 1982-04-23 | Cird | 1,8-DIHYDROXY-9-ANTHRONES SUBSTITUTED IN POSITION 10 AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS |
FR2495934A1 (en) * | 1980-12-15 | 1982-06-18 | Cird | COMPOSITION FOR THE TREATMENT OF PSORIASIS BASED ON SUBSTITUTED-1,8-DIHYDROXY-1,8-ANTHRONE-9 |
-
1984
- 1984-06-13 FR FR8409203A patent/FR2565966B1/en not_active Expired
-
1985
- 1985-06-12 SE SE8502910A patent/SE459807B/en not_active IP Right Cessation
- 1985-06-12 BE BE0/215174A patent/BE902642A/en not_active IP Right Cessation
- 1985-06-12 CH CH2510/85A patent/CH664557A5/en not_active IP Right Cessation
- 1985-06-12 NL NL8501699A patent/NL8501699A/en not_active Application Discontinuation
- 1985-06-12 CA CA000483819A patent/CA1253859A/en not_active Expired
- 1985-06-12 DE DE19853521074 patent/DE3521074A1/en not_active Withdrawn
- 1985-06-12 IT IT21130/85A patent/IT1190365B/en active
- 1985-06-12 JP JP12639185A patent/JPS6140238A/en active Pending
- 1985-06-12 DK DK265185A patent/DK265185A/en unknown
- 1985-06-13 GB GB08514973A patent/GB2160864B/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
DE3521074A1 (en) | 1985-12-19 |
FR2565966B1 (en) | 1986-08-29 |
DK265185A (en) | 1985-12-14 |
BE902642A (en) | 1985-12-12 |
GB2160864A (en) | 1986-01-02 |
CA1253859A (en) | 1989-05-09 |
IT1190365B (en) | 1988-02-16 |
SE8502910L (en) | 1985-12-14 |
IT8521130A0 (en) | 1985-06-12 |
DK265185D0 (en) | 1985-06-12 |
GB2160864B (en) | 1987-12-31 |
FR2565966A1 (en) | 1985-12-20 |
NL8501699A (en) | 1986-01-02 |
CH664557A5 (en) | 1988-03-15 |
SE8502910D0 (en) | 1985-06-12 |
GB8514973D0 (en) | 1985-07-17 |
SE459807B (en) | 1989-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS62234078A (en) | Benzopyranyl and benzothiopyranyl benzene compound, its production and cosmetics and drug for human and animal | |
JPH03120273A (en) | Disubstituted acetylene having retinoid-like activity | |
WO1991014673A1 (en) | Novel process for producing benzoic acid derivative | |
US20050148590A1 (en) | Disubstituted chalcone oximes as selective agonists of RAR retinoid receptors | |
EP0272478B1 (en) | Glycyrrhetic acid derivatives and use thereof | |
JPS6140238A (en) | 10_aryl_1,8_dihydroxyanthrone, manufacture and medicinal or cosmetic composition | |
US4889865A (en) | 10-aryl-1,8-dihydroxy-9- anthrones and their esters | |
US4007271A (en) | Dermatalogical compounds and compositions | |
JPH0130821B2 (en) | ||
US4755530A (en) | 1-hydroxy-8-acyloxy-10-acyl anthrones, process for their preparation and their use in human or veterinary medicines and in cosmetic formulations | |
EP2922834B1 (en) | 1-(dimethylamino)ethyl-substituted 6h-benzo[c]chromen-6-ones against senile dementia | |
GB2162175A (en) | 1,8-diacyloxy-10-acylanthrones | |
US6635786B2 (en) | Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use | |
JPS62187431A (en) | Mono-, di- and tri-ester of 1,8-dihydroxy-10-phenyl-9-anthrone or 9-anthranol, manufacture and medicinal and cosmetic composition | |
JPS6013761A (en) | Novel pyridyl ether derivative | |
EP0123605B1 (en) | N-cyclopropylmethyl-2-oxo-3-diparamethoxyphenyl-5,6-triazines, process for its preparation and their use as pharmaceutical preparations | |
JPH02145572A (en) | N-substituted amide | |
HU188239B (en) | Process for the production of new resorcinol-derivatives and of therapeutic preparations containing them | |
JPH10511641A (en) | Diarylethylene metallocene derivative, process for producing the same, and pharmaceutical composition containing the derivative | |
JPS61129183A (en) | Chroman derivative and manufacture | |
JPS6140280A (en) | 5,6_dihydro_4h_cyclopenta(b)thiophene_6_ carboxylic acid, manufacture and medicinal composition | |
US4841097A (en) | Dialkanoyloxybenzylidene dialkanoate | |
CA1234572A (en) | Process for preparing pyridinecarboxylic esters of dopamine and of its n-alkyl derivatives | |
US4195179A (en) | 5-(Indol-3-ylmethylene)-1,3-dimethyl-2-methylamino-4-imidazolidinone | |
JPS59134785A (en) | Benzhydrylpiperazine derivative |